etoposide has been researched along with paclitaxel in 682 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.15) | 18.7374 |
| 1990's | 143 (20.97) | 18.2507 |
| 2000's | 300 (43.99) | 29.6817 |
| 2010's | 206 (30.21) | 24.3611 |
| 2020's | 32 (4.69) | 2.80 |
| Authors | Studies |
|---|---|
| Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
| Heijn, M; Hooijberg, JH; Lankelma, J; Scheffer, GL; Szabó, G; Westerhoff, HV | 1 |
| Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Belinsky, MG; Chen, ZS; Hopper-Borge, E; Kotova, E; Kruh, GD; Shchaveleva, I | 1 |
| Thakker, DR; Troutman, MD | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bacherikov, VA; Chen, CH; Chou, TC; Lin, YW; Liu, LF; Su, TL; Tsai, TJ; Zhang, X | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bednarski, PJ; Kaufmann, D; Kühne, S; Müller, C; Pfaller, T; Pojarová, M; Vogel, S; von Angerer, E | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chang, CY; Chang, JY; Chiang, YK; Coumar, MS; Hsieh, HP; Kuo, CC; Lai, MJ; Liou, JP; Reddy, GR; Tan, UK; Wu, SY; Yeh, JY | 1 |
| Chen, GQ; Han, QB; Huang, SX; Pu, JX; Sun, HD; Wu, YL; Xiao, WL; Yang, LB; Zhao, Y | 1 |
| Bae, MA; Choi, SU; Choi, YL; Heo, JN; Kim, BT; Kim, JK; Min, YK | 1 |
| Chen, GQ; Ding, LS; Huang, SX; Li, X; Pu, JX; Sun, HD; Wu, YL; Xiao, WL; Yang, LB; Zhao, Y | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Béliveau, R; Castaigne, JP; Ché, C; Currie, JC; Demeule, M; Lacoste, MC; Régina, A; Thiot, C; Yang, G | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Calvo, A; Font, M; Ibáñez, E; Palop, JA; Plano, D; Prior, C; Sanmartín, C | 1 |
| Bo, J; Chen, S; Cheng, H; Liu, J; Liu, Y; Wan, J; Wang, J; Yang, F; Yang, J; Zhou, GC | 1 |
| Cikotiene, I; Díaz-Rodríguez, E; Domínguez-Kelly, R; Freire, R; León, LG; Padrón, JM; Pandiella, A; Ríos-Luci, C | 1 |
| Chang, CY; Chang, JY; Kuo, CC; Lai, WY; Lee, HY; Liou, JP; Nien, CY; Shih, KH; Wu, CH | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Huang, J; Jiang, S; Li, N; Li, X; Wang, JH; Wang, Y; Xiao, W; Zhang, P | 1 |
| Font, M; Ibáñez, E; Lizarraga, E; Palop, JA; Plano, D; Sanmartín, C | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Budovská, M; Mezencev, R; Mojžiš, J; Pilátová, M; Varinská, L | 1 |
| Chang, CY; Chang, JY; Chang, YT; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Liu, YM; Mehndiratta, S; Nien, CY; Pan, SL; Su, MC; Wu, JS; Wu, SY | 1 |
| Chen, H; Ding, G; Li, L; Liu, X; Song, B; Wang, H; Zhang, H; Zou, Z | 1 |
| Chang, CY; Chang, JY; Chuang, HY; Kuo, CC; Lee, HY; Liou, JP; Yeh, TK | 1 |
| Chai, HB; Deng, Y; Fuchs, JR; Gallucci, JC; Kanagasabai, R; Kinghorn, AD; Lantvit, DD; Ninh, TN; Ren, Y; Soejarto, DD; Swanson, SM; Yalowich, JC; Yu, J | 1 |
| Ganga Reddy, V; Jain, N; Kamal, A; Paidakula, S; Polepalli, S; Shankaraiah, N; Srinivasa Reddy, T; Srinivasulu, V | 1 |
| Ji, XY; Jin, J; Li, ZR; Shen, JJ; Wang, Z; Wu, LT; Xue, ST; Zhan, YC | 1 |
| Chang, CY; Chang, JY; Chen, MC; Chiang, YF; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Mehndiratta, S | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Babaev, VM; Belenok, MG; Kataev, VE; Mironov, VF; Rizvanov, IKh; Semenov, VV; Semenova, MN; Strobykina, IY | 1 |
| Chang, CY; Chang, JY; Chuang, HY; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP | 1 |
| Alim, Z; Beydemir, Ş | 1 |
| Bahulayan, AK; Kabeer, FA; Madhusoodhanan, AR; Nair, MS; Prakasan, N; Prathapan, R; Rajalekshmi, DS; Varughese, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Han, HW; Hu, C; Lu, GH; Qi, JL; Qiu, HY; Sun, WX; Wang, XM; Yang, RW; Yang, YH | 1 |
| Bagul, C; Bhattacharjee, D; Jain, N; Kamal, A; Kapure, JS; Shaik, SP; Subba Rao, AV; Sultana, F; Vishnuvardhan, MVPS | 1 |
| Chen, SW; Feng, SL; Guan, XW; Hui, L; Ma, YZ; Xu, XH | 1 |
| Han, HW; Ji, YJ; Lin, HY; Lu, GH; Qi, JL; Sun, WX; Wan, Y; Wang, XM; Yang, YH | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
| Chen, JT; Ma, R; Mu, Q; Sun, SC; Xu, XL; Zhu, XF | 1 |
| Burdette, JE; Chai, HB; Cole, MS; Fuchs, JR; Herrera, D; Huntsman, AC; Kanagasabai, R; Karmahapatra, S; Kinghorn, AD; Patel, PA; Ren, Y; Woodard, JL; Yalowich, JC; Young, AN | 1 |
| Guan, YF; Lam, CS; Lee, KM; Lee, MML; Liu, KL; Pan, WH; Tai, WCS; Tsang, SW; Wong, WY; Xia, YX; Xie, WJ; Xu, XY; Zhang, HJ | 1 |
| Capuzzi, SJ; Chang, LC; Goto, M; Hsieh, KY; Hsu, PL; Lee, KH; Li, J; Li, KP; Morris-Natschke, SL; Zhang, YC | 1 |
| Xu, Z; Zhang, L | 1 |
| Jana, K; Manna, T; Misra, AK; Pal, K | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Bong Oh, K; Ho Lee, G; Hong, S; Jang, K; Ju Han, H; Kook Lee, S; Kyung Kim, W; Lee, J; Park, HG; Shin, J; Sub Byun, W; Woo Ha, M; Yang, J; Yang, S | 1 |
| Kolonias, D; Lampidis, TJ; Rubin, RW; Savaraj, N | 1 |
| Gottesman, MM; Mickisch, GH; Pai, LH; Pastan, I | 1 |
| Abel, G; Kelland, LR | 1 |
| Kudo, R; Sagae, S | 1 |
| Weiss, RB | 1 |
| Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y | 1 |
| Jampel, HD; Koya, P; Leong, K; Quigley, HA | 1 |
| Yalowich, JC | 1 |
| Bunn, PA; Kelly, KL | 1 |
| Fujiwara, Y; Inomata, M; Kaneko, A; Kawashima, K; Kunikane, H; Saijo, N; Tanaka, Y | 1 |
| Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W | 1 |
| Ireland, CM; Pittman, SM | 1 |
| Green, MR; Lilenbaum, RC; MacManus, DA | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ | 1 |
| Johnson, DH | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC | 1 |
| Bonomi, P; Faber, LP; Lincoln, S; Recine, D | 1 |
| Greco, FA; Hainsworth, JD; Stroup, SL | 2 |
| Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Ettinger, DS; Finkelstein, DM; Johnson, DH; Sarma, RP | 1 |
| Haller, U; Koechli, OR; Perras, JP; Rodriguez, M; Schaer, GN; Schenk, V; Sevin, BU; Steren, A; Untch, M | 1 |
| Chang, AY; Ettinger, DS; Johnson, DH | 1 |
| Friedland, D; Gorman, G; Treat, J | 1 |
| Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y | 1 |
| Cook, J; Fisher, J; Goldspiel, B; Hahn, SM; Kaufman, D; Liebmann, JE; Mitchell, JB; Venzon, D | 1 |
| Jampel, HD; Leong, KW; Quigley, HA; Thibault, D; Uppal, P | 1 |
| Tritton, TR; Vichi, PJ | 1 |
| Goodin, S; Gosland, M; Hoffman, T; Tsuboi, C; Vore, M | 1 |
| Bollag, D; Lazarides, E; McQueney, PA; Woods, CM; Zhu, J | 1 |
| Ashby, J | 1 |
| Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R | 1 |
| Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
| Daxenbichler, G; Lang, T; Marth, C; Müller-Holzner, E; Widschwendter, M | 1 |
| Aziz, SM; Crooks, PA; Gillespie, MN; Gosland, MP; Olson, JW; Tofiq, S; Tsuboi, CP | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
| Balkenende, AY; Slaper-Cortenbach, IC; van den Berg, H; van der Schoot, CE; Van Leeuwen, EF; Vervoordeldonk, SF; von dem Borne, AE | 1 |
| Jones, WB; Lewis, JL; Schneider, J; Shapiro, F | 1 |
| Greco, FA; Hainsworth, JD | 5 |
| Holm, B; Jensen, PB; Sehested, M | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L | 1 |
| Harstrick, A; Klaassen, U; Schleucher, N; Schröder, J; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Lehr, JE; Naik, H; Pienta, KJ | 1 |
| Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM | 1 |
| Ogretmen, B; Safa, AR | 1 |
| Baughman, TM; Bumol, TF; Cao, J; Dantzig, AH; Ehlhardt, WJ; Law, KL; Shepard, RL; Starling, JJ | 1 |
| Anteby, SO; Edelman, DZ; Peretz, T | 1 |
| Gallant, G; Tsao, MS; Viallet, J | 1 |
| Basu, A; Saijo, N; Weixel, K | 1 |
| Crilly, R; Fromm, D; Kessel, D; Luo, Y; Webber, J | 1 |
| Cannistra, SA; Korsmeyer, S; Strobel, T; Swanson, L | 1 |
| Fennelly, D; Gogas, H | 1 |
| Davey, MW; Davey, RA; Marks, DC; Su, GM | 1 |
| Alberts, DS; Brooks, DJ | 1 |
| Buckwalter, CA; Perez, EA; Reid, JP | 1 |
| Bunn, PA; Kelly, K | 2 |
| Bunn, PA | 1 |
| Brown, JM; Dorie, MJ | 1 |
| Beesley, JS; Hamilton, TC; Johnson, SW; Laub, PB; Ozols, RF | 1 |
| Armistead, DM; Boger, J; Duffy, JP; Galullo, V; Germann, UA; Harding, MW; Mason, VS; Saunders, JO; Shlyakhter, D; Zelle, RE | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A | 1 |
| Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM | 1 |
| Bonomi, P; Johnson, D; Kim, K; Kusler, J | 1 |
| Oliver, RT | 1 |
| Bertola, A; Boiocchi, M; Corona, G; Sorio, R; Toffoli, G | 1 |
| Erland, JB; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT | 1 |
| Boyer, MJ; McKeage, MJ; Millward, MJ; Olver, IN; Richardson, G; Zalcberg, J | 1 |
| Bible, KC; Kaufmann, SH | 1 |
| Harstrick, A; Kasimir-Bauer, S; Stahl, M | 1 |
| Murray, N | 1 |
| Benito, D; Camps, C; Felip, E; González-Larriba, JL; López-Cabrerizo, MP; Massuti, B; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM | 1 |
| Bonomi, P; Faber, LP; LaFollette, S; Lincoln, S; Recine, D; Sharma, M; Warren, W | 1 |
| Clamon, GH; Crawford, J; Green, MR; Miller, AA; Neill, HB; Perry, MC | 1 |
| Birch, R; Bobo, C; Greco, FA; Hainsworth, JD; Weaver, CH | 1 |
| Gatzemeier, U; Jagos, U; Kaukel, E; Koschel, G; von Pawel, J | 1 |
| Aebi, S; de las Alas, MM; Fink, D; Howell, SB; Los, G | 1 |
| Colvin, OM | 1 |
| Pienta, KJ; Smith, DC | 2 |
| Motzer, RJ | 1 |
| Ozols, RF | 1 |
| Benaim, E; Blakley, RL; Galipeau, J; Sorrentino, BP; Spencer, HT | 1 |
| Negoro, S | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hopkins, LG; Kalman, LA; Patten, JE; Stroup, SL; Thomas, M | 1 |
| Kaufmann, SH; Rowinsky, EK | 1 |
| Berg, M; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D; Zell, L | 1 |
| Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS | 1 |
| Greco, FA; Hainsworth, JD; Hopkins, LG; Thomas, M | 1 |
| Ettinger, DS | 2 |
| Eisenhauer, E; Shepherd, FA | 1 |
| Engstrom, C; Green, M; Lilenbaum, RC; MacManus, D | 1 |
| Buckwalter, CA; Perez, EA | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Heimenz, JW; Kronish, LA; Partyka, JS; Perkins, JB; Saez, RA; Sullivan, DM | 1 |
| Davey, MW; Davey, RA; Su, GM | 1 |
| Gehl, J; Mir, LM; Skovsgaard, T | 1 |
| Ain, KB; Aziz, SM; Crooks, PA; Worthen, DR; Yatin, M | 1 |
| Bhalla, KN; Chang, BS; Fang, G; Kim, CN; Perkins, C; Thompson, CB | 1 |
| Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gotthardt, S; Lokich, J; Oliynyk, P | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C; Sonneborn, H; Strong, D | 1 |
| Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC | 1 |
| Bhalla, KN; Fang, G; Kim, CN; Perkins, C | 1 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H | 1 |
| Gottesman, MM; Okochi, E; Sugimoto, Y; Suzuki, M; Tsukahara, S; Tsuruo, T | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Maria Ibrado, A; Miyashita, T; Ray, S; Reed, J | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Baselga, J; Benito, D; Camps, C; Felip, E; González-Larriba, JL; Isla, D; López-Cabrerizo, MP; Massuti, B; Moyano, A; Puerto-Pica, J; Rosell, R; Salamanca, O | 1 |
| Ajani, JA | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Minami, H; Ohtsu, T; Saijo, N; Sasaki, Y | 1 |
| Kalemkerian, GP; Ou, X | 1 |
| Armand, JP; Couteau, C | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Jobe, DR; Kuhn, J; Rizzo, J; Schreeder, MT; Walton, GD | 1 |
| Chikazawa, H; Fujimoto, S | 1 |
| Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL | 1 |
| Hoffman, M; Lesser, M; Rai, K; Xu, JC | 1 |
| Gibson, S; Johnson, GL; Widmann, C | 1 |
| Passaniti, A; Wang, W | 1 |
| Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M | 1 |
| Anderson, NR; Bern, MM; Coco, FV; Dow, E; Lokich, JJ; Oliynyk, P; Sonneborn, H | 1 |
| Cruz, E; Espinoza, AM; Maldonado, V; Melendez-Zajgla, J | 1 |
| Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S | 1 |
| Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| Inoue, H; Kim, R; Ohi, Y; Toge, T | 1 |
| Batrakova, EV; Kabanov, AV; Li, S; Miller, DW | 1 |
| Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M | 1 |
| Fossella, FV; Fox, NJ; Glisson, BS; Hong, WK; Kurie, JM; Lee, JS; Murphy, WK; Nyberg, DA; Perez-Soler, R; Pisters, KM; Ross, MB; Shin, DM | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Bunn, PA; Kelly, K; Murphy, J; Pan, Z; Wood, ME | 1 |
| de Mulder, PH; de Wit, R; Louwerens, M; Rodenhuis, S; Schornagel, J; Verweij, J | 1 |
| Bonomi, P; Cella, D; Fairclough, D; Jiroutek, M; Johnson, D; Kim, K; Kugler, J; Rowinsky, E | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Boisdron-Celle, M; Boulanger, N; Gamelin, E | 1 |
| Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Kazierad, D; Khan, AM; Khan, IA; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
| Chang, A; Craffey, M; DeVore, R; Dowlati, A; Jett, J; Johnson, D; Levitan, N; Mackay, W; Remick, SC; Shina, D | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Bains, M; Bajorin, DF; Bosl, GJ; Flombaum, C; Macapinlac, HA; Mariani, T; Mazumdar, M; Motzer, RJ; Reich, L; Sheinfeld, J; Tong, WP | 1 |
| Choy, H; Cmelak, AJ; Johnson, DH; Mohr, PJ; Shyr, Y | 1 |
| Ausema, B; Kamps, W; Kok, JW; Kolk, D; Nijhof, W; Sietsma, H; Veldman, RJ; Vellenga, E | 1 |
| Bhalla, KN; Fang, G; Kim, CN; Perkins, CL | 1 |
| Cal, C; Gunaydin, G; Omay, SB; Ozyurt, C; Uslu, R | 1 |
| Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
| Berkowitz, R; Cannistra, SA; Kim, Y; Matulonis, U; Niloff, J; Quartulli, M; Seiden, M; Tung, N | 1 |
| Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Filipeanu, CM; Klappe, K; Kok, JW; Koning, H; Müller, M; Veldman, RJ | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kiamouris, C; Kosmidis, P; Papadimitriou, C; Papakostas, P; Pavlidis, N; Sikiotis, K; Skarlos, DV | 1 |
| Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S | 1 |
| Beketic-Oreskovic, L; Chen, GK; Durán, GE; Mangili, A; Sikic, BI | 1 |
| Andrews, DF; Gilmore, GL; Lister, J; Shadduck, RK; Zeigler, ZR | 1 |
| Connor, TH; Singleton, LC | 1 |
| Ikeda, J | 1 |
| Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R | 1 |
| Burris, HA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT | 1 |
| Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A | 1 |
| Gallagher, CJ; Gupta, RK; Kelsey, S; Lister, TA; Newland, AC; O'Doherty, CA; Oliver, RT; Shamash, J | 1 |
| Dowell, JE; Garrett, AM; Hande, KR; Johnson, DH; Shyr, Y | 1 |
| Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G | 1 |
| Baker, SD; Fleming, GF; Fracasso, PM; Look, KY; McGuire, WP; Muggia, FM; Roth, BJ; Sutton, GP | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Capuano, G; D'Alessandro, V; Lelli, G; Morelli, F; Nanni, L; Palomba, G; Piano, A; Rinaldi, B; Simeon, A; Sirotovà, Z | 1 |
| Cantoni, C; Daga, A; Lunardi, C; Millo, R; Oliveri, M; Puccetti, A | 1 |
| Matsuoka, Y; Shimizu, S; Shinohara, Y; Tsujimoto, Y; Yoneda, Y | 1 |
| Boyer, MJ; Clarke, SJ; Davis, I; Goldstein, D; Millward, MJ; Mitchell, P; Olver, IN; Richardson, G | 1 |
| Chao, Y; Chen, LT; Huang, TS; Shu, CH | 1 |
| Malik, IA | 1 |
| Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P | 1 |
| Crosby, L; Dowlati, A; Levitan, N; Makkar, V; Remick, SC | 1 |
| Goehle, S; Lamb, JR; Ludlow, C; Simon, JA | 1 |
| Biden, TJ; Carpenter, L; Humphries, MJ; Matassa, AA; Reyland, ME | 1 |
| Beyer, J; Bokemeyer, C; Rick, O; Siegert, W | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Agelidou, M; Bania, E; Georgoulias, V; Jordanoglou, J; Kakolyris, S; Kouroussis, C; Mavroudis, D; Papadakis, E; Stavrakakis, J; Tsiafaki, X; Veslemes, M; Vlachonicolis, J | 1 |
| Lorenz, SA; Maziarz, EP; Wood, TD | 1 |
| Brugarolas, A; García-Rayo, S; Inogés, S; Martín-Algarra, S; Martínez-Aguillo, M; Ordóñez, JM; Pérez-Calvo, J; Ramón y Cajal, T; Santisteban, M; Subirá, ML | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Aasebø, U; Bremnes, RM; Sundstrøm, S; Vilsvik, J | 1 |
| Baudin, B; Bénéteau-Burnat, B; Bruneel, A; Grenet, K; Mailloux, A; Vaubourdolle, M | 1 |
| Bunn, PA; Crowley, JJ; Gandara, DR; Kelly, K; Livingston, RB; Lovato, L; Roychowdhury, D; Taylor, SA; Zangmeister, J | 1 |
| Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ | 1 |
| Azinovic, I; Brugarolas, A; Fernández-Hidalgo, O; García-Rayo, S; Martín-Algarra, S; Martínez-Aguillo, M; Martínez-Monge, R; Pérez-Calvo, J; Rebollo, J; Subirá, L | 1 |
| Bloomer, WD; Ji, M; Papadopoulou, MV | 1 |
| Le Chevalier, T; Novello, S | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Aboud, M; Ben-Aroya, Z; Butovsky, E; Flügel, RM; Grunspan, A; Hallak, M; Kedar, I; Livneh, E; Löchelt, M; Torgeman, A; Wolfson, M; Zelin, E | 1 |
| Cliby, WA; Kaufmann, SH; Lewis, KA; Lilly, KK | 1 |
| Bensinger, WI; Gooley, T; Heimfeld, S; Holmberg, L; Maloney, D; Rowley, SD; Yu, J | 1 |
| Hassan, SB; Jonsson, E; Karlsson, MO; Larsson, R | 1 |
| Bogush, EA; Bogush, TA; Khrustalev, SA; Koldaeva, EY; Konyaeva, OI; Smirnova, GB | 1 |
| du Bois, A | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Hinterleitner, T; Kerbl, R; Schwinger, W; Smolle Juettner, FM; Urban, C; Zotter, H | 1 |
| De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G | 1 |
| Bernardo, P; Bonomi, P; Cella, D; Johnson, DH; Kugler, JW; Langer, CJ; Manola, J | 1 |
| Thigpen, T | 1 |
| Bookman, MA | 2 |
| Newton, HB; Santi, M; Stevens, C | 1 |
| Leslie, KK | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Beyer, J; Rick, O; Siegert, W | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Martín, M | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Kuroki, T; Ohba, M; Sumitomo, M | 1 |
| Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D | 1 |
| Boletis, J; Chiras, T; Kosmas, C; Kostakis, A; Tsavaris, NB; Vadiaka, M | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Chung, CW; Jo, DG; Jung, YK; Kim, BJ; Kim, IK; Kim, KW; Kwon, YK; Song, YH; Woo, HN | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Aebi, S; Betticher, DC; Calderoni, A; Solenthaler, M; von Briel, C | 1 |
| Hwang, PH; Lee, DY; Oh, Y; Yi, HK | 1 |
| Hensley, ML | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| Nathan, C; Shen, C | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N | 1 |
| Arnt, CR; Chiorean, MV; Gores, GJ; Heldebrant, MP; Kaufmann, SH | 1 |
| Cosaert, J; Quoix, E | 1 |
| Boldt, S; Kolch, W; Weidle, UH | 1 |
| Krüger, I; Lindenfelser, R; Scherwitz, P | 1 |
| D'Orazio, A; Gibson, AD | 1 |
| Gerinière, L; Souquet, PJ | 1 |
| Chen, XB; Li, DX | 1 |
| Clark, AS; Dennis, PA; Streicher, S; West, K | 1 |
| Choy, H; Gandara, D; Mattson, K; Vokes, EE | 1 |
| Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L | 1 |
| Gatzemeier, U; Grunwald, F; Hessler, S; Jagos, U; Kaukel, E; Koschel, G; Reck, M; von Pawel, J | 1 |
| Antón, LM; Constenla, M; Domínguez, S; Dorta, J; Esteban, E; García-Girón, C; Gómez Aldavarí, JL; Gonzalez-Barón, M; Gracia, M; Lacave, AJ; López, E; López, R; Martín, G; Mel, JR; Peláez, I; Rodríguez, R; Sevilla, I; Valladares, M; Vieitez, JM | 1 |
| Miao, L; Wang, Y; Wu, M; Yi, P; Zhai, Z; Zhang, W | 1 |
| Naito, K | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Bunn, PA; Simon, GR | 1 |
| Beitler, JJ | 1 |
| Bélanger, MM; Couet, J; Roussel, E | 1 |
| Bonomi, P; Cella, D; Eton, DT; Fairclough, DL; Johnson, DH; Yount, SE | 1 |
| Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF | 1 |
| Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R | 1 |
| Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM | 1 |
| Dou, QP; Kuhn, DJ; Pross, S; Smith, DM; Whiteside, TL | 1 |
| Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC | 1 |
| Hara, N; Moritake, K; Osago, H; Shingu, T; Terashima, M; Tsuchiya, M; Uemura, T; Yamada, K; Yamasaki, T | 1 |
| Chuang, TC; Kao, MC; Law, SL; Lee, YJ; Li, JW; Lin, YS; Liu, JY; Wang, V | 1 |
| Albertsson, P; Lennernäs, B; Lennernäs, H; Norrby, K | 1 |
| Johnson, DH; Laskin, J; Sandler, A | 1 |
| Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J | 2 |
| Davey, MW; Davey, RA; Locke, VL | 1 |
| Aquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F | 1 |
| Fiorica, JV | 1 |
| Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK | 1 |
| Bar-Sela, G; Gaitini, D; Haim, N; Steiner, M; Tsalic, M | 1 |
| Choi, HJ; Jin, YH; Lee, SK; Park, BD; Yim, H | 1 |
| Carty, M; Gilmore, PM; Harkin, DP; Johnston, PG; Kennedy, RD; Mullan, PB; Quinn, JE | 1 |
| Greco, FA | 1 |
| Ball, ED; Chen, J; Mokotoff, M; Shultz, LD; Zhong, R; Zhou, J | 1 |
| La Mura, N; Lombardi, D; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A | 1 |
| Syed, S | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| Christodoulou, J; Haferlach, T; Schnittger, S; Schoch, C | 1 |
| Chansky, K; Crowley, J; Edelman, MJ; Gandara, DR; Gaspar, LE; Leigh, B; Livingston, R; Taylor, SA; Weiss, GR | 1 |
| Gabbert, HE; Gerharz, CD; Reinecke, P; Schmitz, M; Steckstor, M | 1 |
| Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K | 1 |
| Francia, G; Green, SK; Isidoro, C; Kerbel, RS | 1 |
| Barceló, R; Ferreiro, J; Fuente, N; López Vivanco, G; Muñoz, A; Rubio, I | 1 |
| Basu, A; Huang, J; Kumar Biswas, S; Persaud, S | 1 |
| Driver, D; Giles, C; Harland, SJ; Haynes, R; Kanfer, EJ; McNeish, IA; Newlands, ES; Rustin, GJ; Seckl, MJ | 1 |
| Shimizu, E | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Farr, GH; Geoffroy, FJ; Hatfield, AK; Hillman, S; Johnson, EA; Krook, JE; Levitt, R; Maillard, JA; Marks, RS; Perez, EA; Tazelarr, HD | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Beyer, J; Bokemeyer, C; Braun, T; Hartmann, JT; Hartmann, M; Pottek, T; Rachud, B; Rick, O; Schirren, J; Siegert, W; Weinknecht, S; Weissbach, L | 1 |
| Covens, A; Gerulath, A; Merchandani, DE; Mirchandani, D; Osborne, R | 1 |
| Doyle, A; Edelman, MJ; Gamliel, Z; Hausner, P; Krasna, M; Patel, AB; Sonett, JR; Suntharalingam, M | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Agner, J; Bartek, J; Falck, J; Lukas, J | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Chen, LK; Liang, Y; Liu, JL; Xu, GC; Yang, QY; Zhang, LN | 1 |
| Herzog, TJ | 1 |
| Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J | 1 |
| Kang, WK; Ko, U; Lee, I; Park, C | 1 |
| Biron, P; Bui, B; Caty, A; Culine, S; Curé, H; De Revel, T; Delva, R; Droz, JP; Duclos, B; Fizazi, K; Gligorov, J; Gomez, F; Gravis, G; Guillemaut, S; Lotz, JP; Peny, J; Provent, S; Ségura, C; Théodore, C; Viens, P | 1 |
| Hausmaninger, H; Heilmann, V; Huebner, G; Nitsch, T; Possinger, K; Schippinger, W; Schmid, P; Schultze, W; Wischnewsky, M | 1 |
| Sugiyama, T | 1 |
| Mikami, K; Miki, T; Mizutani, Y | 1 |
| André, A; Braekman, JC; Bruyneel, F; Darro, F; Decaestecker, C; Dewelle, J; El Yazidi, M; Guissou, P; Kiss, R; Nacoulma, O; Simon, G; Tuti, J; Van Quaquebeke, E | 1 |
| Akbulut, H; Altinbas, M; Baltali, E; Boruban, C; Büyükcelik, A; Coşkun, S; Demirkazik, A; Erkisi, M; Icli, F; Komurcu, S; Onur, H; Sak, SD; Sencan, O; Senler, FC; Uner, A; Yalcin, B; Zengin, N | 1 |
| Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM | 1 |
| Castine, M; Greco, FA; Hainsworth, JD; Kalman, L; Sylvester, L | 1 |
| Debatin, KM; Fulda, S | 1 |
| Bushman, F; Groschel, B | 1 |
| Díaz-Montero, CM; McIntyre, BW | 1 |
| Epstein, AL; Hu, P; Khawli, LA | 1 |
| Beijnen, JH; Chhatta, AA; Huisman, MT; Schinkel, AH; van Tellingen, O | 1 |
| Ansari, R; Belani, CP; Lee, JS; Lilenbaum, R; Natale, RB; Robert, F; Rowland, K; Socinski, MA; Waterhouse, D | 1 |
| Brown, J; Burke, TW; Deavers, MT; Gershenson, DM; Munsell, MF; Ramondetta, LM; Shvartsman, HS | 1 |
| Bakalarz, R; Banasik, A; Góźdź, S; Lankoff, A; Lesisz, D; Lisowska, H; Padjas, A; Wojcik, A | 1 |
| De, S; Miller, DW; Robinson, DH | 1 |
| Kekre, N; McLachlan, A; McNulty, J; Pandey, S | 1 |
| Ansari, RH; Ellerton, J; Green, MR; Herndon, JE; Kelly, K; Marks, RS; Miller, AA; Niell, HB; Otterson, G; Perry, MC; Sandler, AB; Vokes, EE; Watson, DM | 1 |
| Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D | 1 |
| Abrams, RA; Berkey, BA; Byhardt, RW; Curran, WJ; Duncan, PJ; Ettinger, DS; Fontanesi, J; Machtay, M; Movsas, B | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Broggini, M; Kei Lee, M; Sabapathy, K; Siddique, MM; Vikhanskaya, F | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Lin, C; Liu, ZR; Yang, L | 1 |
| Muehlbauer, PA; Schuler, MJ | 1 |
| Adjei, AA; Creagan, ET; Croghan, G; Frytak, S; Giordano, KF; Jatoi, A; Jett, JR; Marks, R; Molina, J; Okuno, S; Richardson, RL | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| Kekre, N; McNulty, J; Naderi, J; Pandey, S | 1 |
| Alshehadat, S; Sahmoun, AE | 1 |
| Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S | 1 |
| Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS | 1 |
| Rexer, FH | 1 |
| Alvarnas, J; Chow, W; Doroshow, JH; Frankel, P; Kogut, N; Leong, LA; Lim, D; Margolin, KA; McNamara, M; Morgan, RJ; Schriber, J; Shibata, S; Somlo, G; Stalter, S; Twardowski, P; Yen, Y | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R | 1 |
| Hiramatsu, Y; Hongo, A; Kodama, J; Nakamura, K; Ojima, Y; Seki, N | 1 |
| Baas, P; Belderbos, JS; Burgers, JA; Kwa, HB; Senan, S; van Bochove, A; van Meerbeeck, JP; van Tinteren, H | 1 |
| Gibson, SB; Henson, ES; Hu, X | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Jankovic, D; Kanazir, S; Markovic, ID; Markovic, JZ; Pesic, M; Rakic, L; Ruzdijic, S | 1 |
| Amikura, T; Aoki, Y; Banzai, C; Nishikawa, N; Sekine, M; Suzuki, M; Tanaka, K; Yokoo, T | 1 |
| Eberhardt, W; Pöttgen, C; Stuschke, M | 1 |
| Baldini, E; Conte, PF; Del Freo, A; Fabbri, A; Falcone, A; Innocenti, F; Pennucci, MC; Prochilo, T; Russo, F; Tibaldi, C | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Argyraki, A; Christophylakis, Ch; Georgoulias, V; Geroyianni, A; Kakolyris, S; Karvounis, N; Kouroussis, Ch; Tsaroucha, E; Veslemes, M | 1 |
| Depierre, A | 1 |
| Blumenthal, DK; Chen, J; Cheung, AK; Lee, RM; Li, L; Liu, J; Masaki, T; Yang, HS | 1 |
| Li, Z; Liu, Z; Thiele, CJ; Woo, CW; Zhang, J | 1 |
| Daly, BD; Dipetrillo, TA; Fernando, HC; Kachnic, LA; Ketchedjian, A; Morelli, DM; Shemin, RJ | 1 |
| Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
| Greco, FA; Hainsworth, JD; Litchy, S; Spigel, DR | 1 |
| Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
| Cheng, JQ; He, L; Kruk, P; Nicosia, SV; Yang, H | 1 |
| Scorilas, A; Talieri, M; Thomadaki, H | 1 |
| Katakami, N | 1 |
| Fukumori, T; Harada, A; Hayashi, H; Izaki, H; Kanayama, HO; Kishimoto, T; Nishitani, MA; Takahashi, M; Tanimoto, S; Taue, R; Yamamoto, Y | 1 |
| Berdel, WE; Frickhofen, N; Haas, R; Heimpel, H; Hinke, A; Hossfeld, DK; Kreienberg, R; Kuhn, W; Möbus, V; Opri, F; Sandherr, M; Schneeweiss, A; Thomssen, C | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J | 1 |
| Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E | 1 |
| Chansky, K; Crowley, JJ; Davies, AM; Gandara, DR; Gaspar, LE; Lau, DH; Leigh, BR; Weiss, GR; Wozniak, AJ | 1 |
| Hagan, CR; Rudin, CM | 1 |
| Goldman, A; Pommier, Y; Sordet, O | 1 |
| Atweh, GF; Mistry, SJ | 1 |
| Bacik, J; Bains, M; Bajorin, D; Bosl, GJ; Budnick, A; Deluca, J; Ishill, N; Kondagunta, GV; Mazumdar, M; Motzer, RJ; Reich, L; Sheinfeld, J | 1 |
| Ling, MT; Wang, X; Wong, YC; Zhang, X | 1 |
| Backendorf, C; Noteborn, MH; Olijslagers, SJ; Zhang, YH | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| Coley, HM; Hughes, MP; Labeed, FH; Thomas, H | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Kim, DM; Lee, S; Lim, SK; Park, SY; Park, YN; Rhee, Y; Song, SY; Youn, JC | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
| Gaucher, G; Leroux, JC; Poreba, M; Ravenelle, F | 1 |
| Feng, YL; Li, JD; Li, MD; Liu, JH; Shi, HL; Xiao, Y | 1 |
| Yoneda, S | 1 |
| Brozmanová, K; Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Risnyovzská, Z; Sálek, T; Svetlovská, D; Sycová-Milá, Z | 1 |
| Droz, JP; Fléchon, A | 1 |
| Frank, H; Fuchs, J; Heitmann, H; Herberts, T; Ruck, P; Seitz, G; Warmann, SW | 1 |
| Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF | 1 |
| Chen, A; Ding, F; Liu, Z; Luo, A; Ren, S; Yu, Z; Zhang, L; Zhang, S | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Murakawa, Y; Nishino, Y; Ohori, H; Ohtsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T | 1 |
| Biesterfeld, S; Hoffarth, S; Huber, C; Kröll, M; Schuler, M; Wesarg, E; Wiewrodt, R | 1 |
| Biesma, B; de Jong, WK; Groen, HJ; Koolen, MG; Kwa, HB; Smit, EF; van Bochove, A; van Tinteren, H; Willems, LN | 1 |
| Seto, T | 1 |
| Fu, J; Liang, M; Su, DM; Zhang, P | 1 |
| Chen, JJ; Fan, DM; Li, TT; Liu, YW; Liu, ZG; Zhao, LN | 1 |
| Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S | 1 |
| Guang, ZZ; Jiang, WQ; Li, ZM; Liu, ZC; Yang, DJ; Zhou, JM; Zhu, XF; Zhu, ZY | 1 |
| Bae, SN; Jung, SG; Kim, CJ; Kim, SJ; Lee, C; Na, YJ | 1 |
| Marwaha, S; North, SA; Venner, PM | 1 |
| Galsky, MD; Kondagunta, V; Sonpavde, G | 1 |
| Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Beyer, J; Bokemeyer, C; Casper, J; Derigs, G; Gauler, T; Gerl, A; Hartmann, JT; Horger, M; Kuczyk, MA; Mayer-Steinacker, R; Metzner, B; Rick, O; Schleicher, J | 1 |
| Benoit, JP; Garcion, E; Lacoeuille, F; Lamprecht, A | 1 |
| Hsu, PC; Hung, HC; Liao, YF; Liu, CC; Liu, GY; Tsay, GJ | 1 |
| Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM | 1 |
| Lindsay, I; Newlands, ES; Savage, PM; Schmid, P; Sebire, NJ; Seckl, MJ; Short, D; Wang, J | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Gao, J; He, Z; Li, X; Li, Y; Liu, M; Tang, H; Wang, Q; Zheng, J | 1 |
| Castino, R; Démoz, M; Isidoro, C; Nicotra, G; Peracchio, C; Salini, A; Trincheri, NF; Valente, G | 1 |
| Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M | 1 |
| Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y | 1 |
| Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X | 1 |
| Scorilas, A; Thomadaki, H | 1 |
| Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J | 1 |
| Antoniou, D; Athanasiadis, A; Dimitroulis, J; Giamboudakis, P; Karaindros, D; Katis, K; Koutantos, J; Rapti, A; Rigatos, S; Stathopoulos, GP; Stathopoulos, J; Toumbis, M; Tsikritsaki, K | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML | 1 |
| Bernardo, P; Horn, L; Johnson, DH; Levitan, N; Levitt, ML; Sandler, A; Wagner, H | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Berek, JS; Brady, M; Hutson, A; Markman, M | 1 |
| Aruga, C; Aubrecht, J; Bauer, D; Boitier, E; Deng, S; Dickinson, D; Ellinger-Ziegelbauer, H; Fornace, AJ; Fostel, JM; Grenet, O; Gu, Y; Hoflack, JC; Le Fevre, AC; Shiiyama, M; Smith, R; Snyder, RD; Spire, C; Tanaka, G | 1 |
| Lv, L; Song, B; Song, X; Wang, X; Wei, L; Xie, L; Yu, J | 1 |
| Borovskaya, TG; Gol'dberg, VE; Pachomova, AV; Perova, AV; Poluektova, ME | 1 |
| Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Basu, S; Faber, LP; Kim, AW; Liptay, MJ; Miller, C; Milman, S; Warren, WH | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Rivera Rosado, LA; Yoshida, T; Zhang, B; Zhang, Y | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Choi, IK; Gao, R; Kaul, SC; Kaur, K; Kim, I; Morrow, G; Ryu, J; Tanguay, RM; Wadhwa, R; Yun, CO | 1 |
| Arslan, C; Kilickap, S | 1 |
| Bains, M; Bajorin, DF; Bosl, GJ; Feldman, DR; Fischer, P; Ishill, N; Motzer, RJ; Patil, S; Reich, LM; Sheinfeld, J; Turkula, S | 1 |
| Ishii, N; Matsuda, T; Morozumi, M; Takagi, D; Terao, T; Yamada, T; Yamashita, T; Yoshinaga, A | 1 |
| Abolmaali, ND; Abramyuk, AM; Tokalov, SV | 1 |
| Chen, JY; Li, J; Zhu, X | 1 |
| Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT | 1 |
| Brandt, BH; Dittmar, T; Haverkampf, S; Meyer-Staeckling, S; Niggemann, B; Reith, G; Schwitalla, S; Seidel, J; Zänker, KS | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Abonour, R; Einhorn, LH; Kesler, KA | 1 |
| Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Anisimov, AP; Cragg, MS; Erenpreisa, J; Huna, A; Ianzini, F; Kosmacek, EA; Salmina, K | 1 |
| Lee, DW; Lee, HN; Lee, KH; Lee, YS; Park, EK; Park, JS | 1 |
| Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Bascoul-Mollevi, C; Beyer, J; De Giorgi, U; Einhorn, L; Fléchon, A; Germà-Lluch, JR; Kollmannsberger, C; Kramar, A; Lorch, A; Lotz, JP; Margolin, K; Massard, C; Necchi, A; Powles, T | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Abrams, RA; Basu, S; Batus, M; Bonomi, P; Faber, LP; Fidler, MJ; Gielda, BT; Liptay, M; Marsh, JC; Warren, WH; Zusag, TW | 1 |
| Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A | 1 |
| Jeremić, B; Miličić, B; Milisavljevic, S | 3 |
| Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D | 1 |
| Abdel-Hady Hemida, R; Abdel-Hady, el-S; El-Shamey, M; Gamal, A | 1 |
| Blagden, S; Gabra, H; Graham, J; Sharma, R | 1 |
| Bi, Y; Calhoun-Davis, T; Chen, X; Coletta, LD; Fokt, I; Klostergaard, J; Li, H; Liu, C; Priebe, W; Qin, J; Skora, S; Tang, DG; Yan, H; Zhang, Q | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M | 1 |
| Charoentum, C; Chewaskulyong, B; Permsuwan, U; Ruengorn, C; Thongprasert, S | 1 |
| Bell-McGuinn, KM; Brogi, E; Elie, BT; Garfall, AL; Joyce, JA; Kester, JC; Olson, OC; Shree, T; Simpson, K; Zabor, EC | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Korbakis, D; Scorilas, A | 1 |
| Aass, N; Albers, P; Collette, L; Daugaard, G; De Santis, M; de Wit, R; Garin, A; Germa-Lluch, JR; Marreaud, S; Skoneczna, I; White, JD; Witjes, AJ | 1 |
| Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E | 1 |
| Bernasconi, S; Bono, F; Broggini, M; Damia, G; Fruscio, R; Ganzinelli, M; Mangioni, C; Perego, P; Ricci, F; Russo, G; Signorelli, M | 1 |
| Lim, L; Powles, T; Rashid, S | 1 |
| Barriger, RB; Bradley, JD; De Petris, L; Kim, TH; Marks, LB; Moreno, M; Palma, DA; Ramella, S; Rengan, R; Rodrigues, G; Senan, S; Stitt, L; Tsujino, K | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T | 1 |
| Feng, DP; Gong, WH; Huang, T; Jiang, GJ; Li, XC; Li, XH; Zou, CP | 1 |
| Arnould, T; De Backer, O; Flamant, L; Hayez, A; Michiels, C; Pierre, M; Poumay, Y; Roegiers, E; Sterpin, C | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| Kretzer, IF; Maranhão, RC; Maria, DA | 1 |
| Eitaki, M; Inanami, O; Meike, S; Yamamori, T; Yasui, H | 1 |
| Carmichael, C; Ferrell, B; Frankel, P; Hsu, J; Margolin, K; Pal, SK; Saikia, J; Stein, CA; Sun, V; Twardowski, P; Yamzon, J | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H | 1 |
| Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J | 1 |
| Du, XH; Mao, WM; Wang, SY; Xu, YP; Zhang, SZ | 1 |
| Spigel, DR | 1 |
| Arnould, T; Fransolet, M; Genin, M; Leclere, L; Maincent, A; Michiels, C; Notte, A; Riquier, H; Sermeus, A | 1 |
| Dimitroulis, J; Kosmas, Ch; Stathopoulos, GP; Stathopoulos, J; Trafalis, D; Tsavdaridis, D | 1 |
| Godoy, HE; Lele, SB; Odunsi, K; Olawaiye, AB; Rauh-Hain, JA; Shahzad, MM | 1 |
| Chen, W; He, Y; Peng, J; Song, W; Zhang, S | 1 |
| Demura, Y; Kimura, H; Morikawa, M; Okazawa, H; Tsuchida, T; Umeda, Y | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W | 1 |
| Kuwano, H; Murakawa, T; Murayama, T; Nagayama, K; Nakajima, J; Sano, A; Tsuchiya, T; Yoshida, Y | 1 |
| Köhler, R; Krammer, PH; Li-Weber, M; Lüpertz, R; Merz, C; Müller, WW; Natoli, A | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Angarita, FA; Meek, E; Rodríguez, JL; Sánchez, JO; Tawil, M; Torregrosa, L | 1 |
| Duque, M; Gupta, A; Saif, MW | 1 |
| Lee, DW; Lee, HN; Lee, JW; Lee, KH; Park, JS; Park, ST | 1 |
| Chou, LC; Chung, CH; Huang, CH; Huang, LJ; Kuo, SC; Lee, FY; Lee, JC; Lien, JC; Way, TD; Wu, JC | 1 |
| Bildat, S; Eberhardt, WE; Fischer, B; Gauler, TC; Grunenwald, D; Krbek, T; Le Chevalier, T; Lepechoux, C; Poettgen, C; Rodrigo, Hde L; Seeber, S; Stamatis, G; Stuschke, M; Theegarten, D; Welter, S | 1 |
| Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Arellano, M; Bumpers, K; Flowers, CR; Heffner, LT; Hutcherson, D; Kaufman, J; King, N; Langston, A; Lechowicz, MJ; Lonial, S; Nooka, A; Shenoy, PJ; Sinha, R; Waller, EK | 1 |
| Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Boutros, PC; Feigen, M; Harris, S; John, T; Lambin, P; Liew, MS; Mitchell, P; Sia, J; Starmans, MH; Tafreshi, A; White, S; Zimet, A | 1 |
| Beuschlein, F; Hantel, C; Jung, S; Mussack, T; Reincke, M | 1 |
| Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T | 1 |
| Cheng, XL; Huang, L; Liao, LM; Lin, JX; Liu, AW; Wu, JB; Zheng, M | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM | 1 |
| Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
| Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V | 1 |
| Bay, JO; Biron, P; Brindel, I; Bui, BN; Caty, A; de Revel, T; Delva, R; Dubot, C; Fizazi, K; Fléchon, A; Gaulet, M; Geoffrois, L; Gligorov, J; Gravis, G; Horn, E; Lotz, JP; Micléa, JM; Provent, S; Roubaud, G; Selle, F; Soares, DG; Temby, I; Wittnebel, S | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Harada, A; Matsuzaki, K; Mishima, M; Takeiri, A | 1 |
| Ashton, E; Hoffman, J; Shafer, A; Szutowska, M | 1 |
| Arce-Lara, C; Devisetty, K; Gore, EM; Kelley, MJ; Moran, A; Santana-Davila, R; Sparapani, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Dragun, AE; Dunlap, NE; Jain, D; Meena, RA; Quillo, AR; Riley, EC; Shaughnessy, JN | 1 |
| Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Fléchon, A; Geoffrois, L; Gravis, G; Habibian, M; Journeau, F; Kerbrat, P; Laplanche, A; Linassier, C; Logothetis, C; Malhaire, JP; Mardiak, J; Martin, AL; Pagliaro, L; Reckova, M; Rolland, F; Roubaud, G; Theodore, C | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Kadalayil, L; KhoshZaban, M; Kuku, S; Ledermann, J; Loddo, M; McCormack, M; Proctor, I | 1 |
| Du, XL; Li, HQ; Lu, CH; Pan, CX; Sheng, XG; Wang, C; Yin, YJ | 1 |
| Ayala, AG; Choi, EK; Divatia, M; Miles, BJ; Okoye, E; Ro, JY | 1 |
| An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C | 1 |
| Asada, H; Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H | 1 |
| Boetticher, NC; Strickler, JG; Toma, AA; Verma, R | 1 |
| Chen, Y; Ding, J; Huan, XJ; Miao, ZH; Song, SS; Sun, YM; Tian, QT; Wang, W; Wang, YQ; Yang, CH; Yi, JM; Zhang, XF | 1 |
| Wang, B; Xu, M; Xu, SF; Yu, XC | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y | 1 |
| Fang, J; Liu, LF; Wu, MJ; Yin, ZM; Yu, AJ; Yu, H; Zhu, JQ | 1 |
| Chen, Y; He, HL; He, LJ; Lin, S; Luo, HQ; Pang, HW; Ren, PR; Shang, CL; Wen, QL; Wu, JB; Xiang, L; Yang, B; Yang, HR; Zhang, JW | 1 |
| Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K | 1 |
| Brames, MJ; Einhorn, LH; Mulherin, BP | 1 |
| Hanna, N; Jalal, SI; Mamdani, H | 1 |
| Asaduzzaman, M; Coombes, RC; Cuella, R; Hu, Y; Li, K; Raguz, S; Shi, H; Yagüe, E; Zhou, Y | 1 |
| Ball, DL; Bedő, J; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B; Wen, SW | 1 |
| Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Bacon, CL; Bracken-Clarke, D; Browne, PV; Conneally, E; Daly, PA; Flynn, C; Gardiner, N; Hayden, PJ; Kennedy, MJ; Lee, G; McCaffrey, J; Ni Chonghaile, M; O'Donnell, DM; O'Kane, G; Power, D; Vandenberghe, E | 1 |
| Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP | 1 |
| Chanvorachote, P; Chaotham, C; Puchsaka, P | 1 |
| Cripe, TP; Currier, MA; Falconi, M; Orienti, I; Phelps, M; Teti, G; Wang, J | 1 |
| Hanai, K; Higure, T; Hoshi, A; Kawamura, Y; Nakajima, N; Nitta, M; Shimizu, Y; Terachi, T | 1 |
| Beyer, J; Lorch, A | 1 |
| Msaouel, P; Tu, SM; Zhang, M | 1 |
| Hattori, Y; Hino, M; Kobayashi, Y; Kurahasi, T; Nakagawa, H; Wada, M | 1 |
| Alvarez, MJ; Ambesi-Impiombato, A; Andrews, SJ; Califano, A; Dela Cruz, FS; Diolaiti, D; Forouhar, F; Glade Bender, JL; Kung, AL; Mansukhani, MM; Marks, LJ; Mitchell, CM; Modzelewski, B; Nagy, PL; Rainey, AR; Turk, AT; Yamashiro, DJ | 1 |
| Daly, M; Kelly, K; Tam, K | 1 |
| Behera, M; Belani, CP; Curran, WJ; Ernani, V; Higgins, KA; Khuri, FR; Owonikoko, TK; Pakkala, S; Pillai, RN; Ramalingam, SS; Saba, NF; Shin, DM; Steuer, CE | 1 |
| Bi, N; Chen, D; Chen, M; Chen, W; Du, L; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Shyr, Y; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Azuma, M; Goto, H; Hanibuchi, M; Kakiuchi, S; Kawano, H; Nishioka, Y; Ogushi, F; Otsuka, K; Saijo, A; Sakaguchi, S; Tezuka, T; Toyoda, Y | 1 |
| Anwer, F; Chan, O; Hamdani, AA; Sokolova, A; Ullah, W | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| Daugel-Dauge, NO; Durnev, AD; Kulakova, AV; Pligina, KL; Zhanataev, AK | 1 |
| Duan, R; Li, C; Wang, F; Yangi, JC | 1 |
| Eze, C; Manapov, F | 1 |
| Bi, N; Liang, J; Wang, L | 1 |
| Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW | 1 |
| Ai, W; Chen, Y; Huang, J; Li, D; Li, G; Si, L; Wu, S; Zhao, G | 1 |
| Richie, JP | 1 |
| Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Akashi, K; Ariyama, H; Baba, E; Doi, G; Harimoto, N; Itoh, S; Kohashi, K; Kusaba, H; Maehara, Y; Nio, K; Oda, Y; Odawara, J; Shimoda, S; Takayoshi, K; Tsuchihashi, K; Tsuruta, N; Yoshihiro, T | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Carden, MA; Greenberg, J; McCarty, JM; Perdahl-Wallace, E | 1 |
| Sun, D; Tang, Y; Yao, J; Zhang, M; Zhao, H; Zhu, Z | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Castellano, G; Torrens, F | 1 |
| Breuer, A; Dal Maso, T; Le Calvé, B; Marx, S; Michiels, C; Van Gysel, M; Wouters, J | 1 |
| Li, B; Song, Y; Zhang, Y; Zhao, D | 1 |
| Dhagat, S; Eswari, JS; Yadav, M | 1 |
| Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y | 1 |
| Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z | 1 |
| Das, M; Diehn, M; Hellyer, JA; Hoang, NT; Jeong, Y; Neal, JW; Niu, X; Padda, SK; Ramchandran, K; Stehr, H; Wakelee, H | 1 |
| Belousov, MV; Gur'ev, AM; Lopatina, KA; Razina, TG; Sadrikina, LA; Safonova, EA; Zueva, EP | 1 |
| Cao, P; Gong, Y; Liang, B; Liu, Y; Lu, Y; Luo, C; Wang, J; Wang, Y; Xu, Y; Xue, J; Yan, T; Zhou, L; Zhou, X; Zhou, Y | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Barberi-Heyob, M; Frochot, C; Jouan-Hureaux, V; Lirdprapamongkol, K; Niamsiri, N; Pramual, S; Svasti, J | 1 |
| Althouse, S; Anouti, B; Durm, G; Hanna, N | 1 |
| Borok, MZ; Burger, H; Busakhala, NW; Campbell, TB; Caruso, SR; Godfrey, C; Hoagland, B; Hosseinipour, MC; Kosgei, J; Krown, SE; MacPhail, P; Matining, RM; Mngqibisa, R; Moser, CB; Mwelase, N; Nokta, M; Nyirenda, M; Okuku, FM; Oliver, VO; Samaneka, W | 1 |
| Bi, N; Chen, D; Chen, M; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Wang, J; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z | 1 |
| Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Fujiwara, M; Fukui, I; Hayashi, T; Komai, Y; Kouno, T; Numao, N; Takeda, H; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Bay, JO; Chatelut, E; Chevreau, C; Delmas, C; Delva, R; Filleron, T; Fléchon, A; Gravis, G; Gross-Goupil, M; Lafont, T; Lotz, JP; Marsili, S; Massart, C; Moeung, S; Thomas, F | 1 |
| Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF | 1 |
| Fujiwara, K; Goto, K; Harada, T; Hayashi, T; Kaneda, H; Kenmotsu, H; Kimura, M; Kogure, Y; Koike, T; Matsui, R; Nishio, M; Nogami, N; Seto, T; Shimizu, S; Shimokawa, M; Suzuki, K; Takiguchi, T | 1 |
| de Carvalho Fraga, CA; de Souza, MG; Farias, LC; Guimarães, ALS; Guimarães, TA; Jones, KM; Xavier, GM | 1 |
| Almeida, A; Bartosch, C; Cruz Pires, M; Peixinho, C | 1 |
| Bay, JO; Chatelut, E; Chevreau, C; Ciccolini, J; Culine, S; Delva, R; Filleron, T; Fizazi, K; Flechon, A; Gallois, Y; Gravis, G; Gross-Goupil, M; Guitton, J; Lelièvre, B; Lotz, JP; Massard, C; Moeung, S; Mourey, L; Olivier, P; Paci, A; Thomas, F | 1 |
| Adabi, M; Ghanbari, H; Hadjighassem, MR; Hosseini Najafabadi, MR; Khosravani, M; Maleki, H; Sadroddiny, E; Webster, TJ | 1 |
| An, J; Huang, M; Huang, Y; Li, C; Li, L; Luo, S; Peng, Y; Wang, J; Wang, Z; Wu, L; Yang, H; Yang, X; Zhang, Y | 1 |
| Chang, CH; Chang, YL; Chen, JS; Hsu, FM; Huang, YL; Lee, JM; Lin, CC; Ma, WL; Yang, JC | 1 |
| Asher, R; Connolly, EA; Forgeson, G; Goh, J; Grimison, P; Hamad, N; Heller, GZ; Hill, S; Joshi, A; Kuchel, A; Lewin, J; Liow, E; McKenzie, J; Tan, A; Tan, H; Toner, G; Tran, B; Tung, ILY; Walpole, E; Wang, Y; Weickhardt, A; Wickham, A; Winstanley, MA; Wong, V | 1 |
| Chatterjee, B; Ganti, S; Pandya, M | 1 |
| Min, S; Zheng, Q; Zhou, Y | 1 |
| Bassett, IV; Busakhala, N; Byakwaga, H; Freedberg, KA; Freeman, EE; Hajny Fernandez, ME; Hyle, EP; Kiprono, S; Laker-Oketta, M; Martin, JN; Maurer, T; McCann, NC; Pei, PP; Reddy, KP; Semeere, A | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Cruz, A; de-Castro-Ríos, A; Lema-Atán, JÁ; Lendoiro, E; López-Rivadulla, M; Paniagua-González, L | 1 |
| Abu-Gharbieh, E; Abuhelwa, AY; Ahmed, M; Alqudah, MAY; Alsoud, LO; Alzoubi, KH; Bustanji, Y; El-Awady, R; El-Huneidi, W; Ramadan, WS; Semreen, AM; Semreen, MH; Shara, M; Soares, NC | 1 |
| Akimov, M; Boiko, S; Dudina, P; Ermolenko, Y; Gelperina, S; Kovshova, T; Malinovskaya, J; Mantrov, S; Merkulova, M; Moiseeva, N; Osipova, N; Senchikhin, I | 1 |
| Che, Y; Chen, J; Chen, Z; Cheng, X; Chu, R; Huang, C; Jiang, J; Kong, B; Li, J; Li, K; Li, L; Liu, P; Pan, X; Song, K; Song, L; Wang, J; Xue, Y; Yao, S; Zhang, X; Zhao, Y | 1 |
| Gillett, S; Hapuarachi, B; Ireson, J; Romanowski, C; Singh, K; Tidy, JA; Winter, MC | 1 |
81 review(s) available for etoposide and paclitaxel
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy | 1994 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Recurrence; Tamoxifen | 1996 |
Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Dexamethasone; Etoposide; Female; Humans; Middle Aged; Neoplasm, Residual; Osteonecrosis; Ovarian Neoplasms; Paclitaxel | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Future trials in germ cell malignancy (GCM) of the testis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials as Topic; Decision Making; Etoposide; Forecasting; Genetic Therapy; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Orchiectomy; Paclitaxel; Patient Participation; Quality of Life; Risk Factors; Safety; Salvage Therapy; Seminoma; Testicular Neoplasms | 1997 |
Drug resistance in the treatment of sarcomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Paclitaxel; Platinum Compounds; Sarcoma | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
Topotecan in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan | 1997 |
The role of carboplatin in the treatment of small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1998 |
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Mitoxantrone; Neoplasm Staging; Paclitaxel; Taxoids; Thiotepa | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Paclitaxel in the treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1999 |
The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Etoposide; Humans; Neoplasms, Unknown Primary; Paclitaxel | 1999 |
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan | 2000 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure | 2001 |
Salvage chemotherapy in relapsed germ cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Testicular Neoplasms; Vinblastine | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Etoposide; Europe; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Platinum compounds in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Mastectomy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Preoperative Care; Severity of Illness Index; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Platinum drugs in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Adjuvant and neoadjuvant treatments for NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids | 2002 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
An advance in small-cell lung cancer treatment--more or less.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Greece; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vincristine | 2003 |
The role of topotecan in the treatment of advanced cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Synergism; Etoposide; Female; Humans; Paclitaxel; Topotecan; Uterine Cervical Neoplasms | 2003 |
Ifosfamide in advanced/disseminated breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Length of Stay; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancoast Syndrome; Pneumonectomy; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
[The second-line chemotherapy for urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Male; Methotrexate; Paclitaxel; Survival Rate; Testicular Neoplasms; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Chemoradiation paradigm for the treatment of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
[Testis germ cell tumours: which chemotherapy, for which patients?].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Positron-Emission Tomography; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Seminoma; Testicular Neoplasms; Testis; Vinblastine | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult | 2010 |
Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Therapeutic Equipoise | 2012 |
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Decision Trees; Etoposide; Europe; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; North America; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage | 2013 |
Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Etoposide; Humans; Paclitaxel; Pancreatic Neoplasms; Receptor, IGF Type 1; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
[Chemotherapy in male external genital organs (testicular and penile cancer)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cryopreservation; Etoposide; Fluorouracil; Humans; Ifosfamide; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Paclitaxel; Penile Neoplasms; Spermatozoa; Testicular Neoplasms; Vinblastine | 2013 |
De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Laparoscopy; Leuprolide; Lymph Node Excision; Lymphatic Metastasis; Male; Meningeal Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pelvis; Prostatic Neoplasms; Robotic Surgical Procedures; Time Factors; Tomography, X-Ray Computed; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Radiotherapy, Adjuvant; Risk Factors | 2015 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Patient Selection; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2017 |
Treatment of Locally Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage | 2017 |
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Thorax | 2017 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Brazil; Carcinogenesis; Carcinoma, Squamous Cell; Cell Proliferation; Computational Biology; Etoposide; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mouth Neoplasms; Neoplasm Proteins; Paclitaxel; Plant Extracts; Plants, Medicinal; Vinblastine | 2021 |
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms | 2022 |
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine | 2022 |
Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Methotrexate; Paclitaxel; Placenta; Pregnancy; Quality of Life; Retrospective Studies; Vincristine | 2023 |
145 trial(s) available for etoposide and paclitaxel
| Article | Year |
|---|---|
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 1995 |
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1995 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Drug Tolerance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1995 |
Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel | 1995 |
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Adenoid Cystic; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sarcoma | 1995 |
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Tolerance; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Thorax | 1995 |
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction | 1995 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis | 1995 |
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Analysis | 1996 |
Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outpatients; Paclitaxel; Survival Analysis | 1996 |
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Remission Induction | 1995 |
A phase I study of etoposide phosphate plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel | 1996 |
Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Tumor Cells, Cultured | 1996 |
Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Treatment Outcome | 1996 |
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 1996 |
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1996 |
Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel | 1997 |
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis | 1997 |
Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 1997 |
Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Diseases; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Radiotherapy; Radiotherapy Dosage | 1997 |
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Pilot Projects | 1997 |
A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage | 1997 |
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 1997 |
Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
Paclitaxel in salvage therapy for germ cell tumors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Cells; Carboplatin; Cisplatin; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 1997 |
Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Thrombocytopenia | 1997 |
One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 1997 |
A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 1998 |
Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Filgrastim; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins | 1998 |
Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1999 |
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Time Factors | 1999 |
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Germinoma; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Testicular Neoplasms | 1999 |
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Treatment Failure | 2000 |
Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Etoposide; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Male; Middle Aged; Paclitaxel; Prospective Studies; Salvage Therapy; Survival Analysis | 2000 |
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis | 2000 |
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia | 2000 |
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Taxoids | 2000 |
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2001 |
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2000 |
Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2001 |
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure | 2001 |
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunomagnetic Separation; Middle Aged; Models, Biological; Ovarian Neoplasms; Paclitaxel; Stem Cells; Time Factors; Transplantation, Autologous; Treatment Outcome | 2001 |
Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2001 |
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Topics: Adult; Aged; Antiemetics; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lorazepam; Male; Middle Aged; Multiple Myeloma; Ondansetron; Paclitaxel; Taxoids; Transplantation, Autologous | 2001 |
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2001 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Random Allocation; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hypothermia, Induced; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Severity of Illness Index; Treatment Outcome | 2002 |
Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi-Square Distribution; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2002 |
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.
Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2003 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Health Status; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2003 |
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States | 2003 |
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan | 2003 |
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome | 2003 |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Failure | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2004 |
[Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Rate | 2004 |
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Survival Analysis; Testicular Neoplasms; Treatment Outcome | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Synergism; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome | 2005 |
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Turkey | 2005 |
Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2005 |
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recombinant Proteins; Survival Rate; Time Factors | 2005 |
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan | 2005 |
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prognosis; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2005 |
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Treatment Outcome; Uterus | 2007 |
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation Injuries; Survival Analysis; Treatment Outcome | 2006 |
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vincristine | 2006 |
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Treatment Outcome | 2006 |
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Stem Cells; Time Factors; Vinblastine; Vinorelbine | 2006 |
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Etoposide; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Stem Cell Transplantation; Treatment Outcome | 2007 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Choriocarcinoma; Cisplatin; Etoposide; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Teratocarcinoma; Testicular Neoplasms | 2007 |
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cause of Death; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Survival Analysis; Testicular Neoplasms | 2007 |
Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance | 2008 |
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism | 2009 |
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Retreatment; Salvage Therapy | 2010 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine | 2012 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors | 2011 |
Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Retrospective Studies; Treatment Outcome | 2012 |
Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Granulosa Cell Tumor; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Tamoxifen; Thrombocytopenia; Treatment Outcome | 2011 |
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2011 |
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Treatment Outcome | 2012 |
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome | 2012 |
Combination of three cytotoxic agents in small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicente
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survivors; Treatment Outcome | 2013 |
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome | 2013 |
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Thiotepa; Treatment Failure; Young Adult | 2014 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Chorionic Gonadotropin; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; International Agencies; Lenograstim; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Precision Medicine; Prognosis; Recombinant Proteins; Survival Rate; Testicular Neoplasms; Young Adult | 2014 |
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2015 |
Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumothorax; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Remission Induction; Safety; Survival Rate; Time Factors | 2015 |
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2015 |
Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiography; Spleen | 2015 |
Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Internationality; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prevalence; Risk Factors; Salvage Therapy; Survival Analysis | 2016 |
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models | 2017 |
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution | 2019 |
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
Topics: Adult; Africa; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomycin; Developing Countries; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Paclitaxel; Progression-Free Survival; Sarcoma, Kaposi; Vincristine | 2020 |
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Monitoring; Etoposide; Female; Genotype; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Pharmacogenetics; Pharmacogenomic Testing; Young Adult | 2020 |
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2021 |
459 other study(ies) available for etoposide and paclitaxel
| Article | Year |
|---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
Topics: Adenosine Triphosphate; Anthracyclines; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Cell Membrane; Daunorubicin; Glutathione; Humans; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
Topics: Biological Transport; Cells, Cultured; Cyclosporine; Estradiol; Glycocholic Acid; Humans; Kinetics; Leukotriene Antagonists; Leukotriene C4; Multidrug Resistance-Associated Proteins; Osmotic Pressure; Propionates; Quinolines; Recombinant Proteins; Transfection | 2003 |
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2003 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
Topics: Acridines; Aminoacridines; Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nitrogen Mustard Compounds; Structure-Activity Relationship; Transplantation, Heterologous | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents.
Topics: Antimitotic Agents; Benzoates; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Hydrazones; Indoles; Pyridines | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
Topics: Anisoles; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Models, Chemical; Naphthalenes; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2008 |
ent-Kaurane diterpenoids from Isodon scoparius.
Topics: Antineoplastic Agents, Phytogenic; Diterpenes, Kaurane; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Isodon; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plants, Medicinal | 2009 |
Synthesis of aristolactam analogues and evaluation of their antitumor activity.
Topics: Antineoplastic Agents; Aporphines; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams | 2009 |
ent-Kaurane diterpenoids from Isodon pharicus.
Topics: Antineoplastic Agents, Phytogenic; Diterpenes, Kaurane; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Isodon; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plants, Medicinal | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Doxorubicin; Etoposide; Female; Humans; Inhibitory Concentration 50; Kinetics; Male; Mice; Peptides | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates.
Topics: Antineoplastic Agents; Apoptosis; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50 | 2011 |
Identification, structural properties and chelating capacity of miltipolone as a broad-spectrum inhibitor to cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Diterpenes; Humans; Iron; Iron Chelating Agents; Isomerism; Models, Molecular; Molecular Conformation; Tropolone; Water | 2011 |
A modular approach to trim cellular targets in anticancer drug discovery.
Topics: Anaphase; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Discovery; Humans; Metaphase; Neoplasms; Oxidation-Reduction; Pyrimidines; Structure-Activity Relationship | 2011 |
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Hydroxyquinolines; Quinolines; Stilbenes; Structure-Activity Relationship; Sulfones; Tubulin Modulators | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Bioactive barrigenol type triterpenoids from the leaves of Xanthoceras sorbifolia Bunge.
Topics: Molecular Structure; Plant Leaves; Sapindaceae; Triterpenes | 2013 |
Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour.
Topics: Antineoplastic Agents; Carbamates; HT29 Cells; Humans; MCF-7 Cells; Models, Molecular; Molecular Conformation; Organoselenium Compounds; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The synthesis and anticancer activity of analogs of the indole phytoalexins brassinin, 1-methoxyspirobrassinol methyl ether and cyclobrassinin.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Jurkat Cells; Magnetic Resonance Spectroscopy; MCF-7 Cells; Phytoalexins; Sesquiterpenes; Stereoisomerism; Thiocarbamates | 2013 |
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Heterocyclic Compounds, 2-Ring; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Mice, Nude; Molecular Structure; Neoplasms; Polymerization; Sulfonamides; Tubulin; Xenograft Model Antitumor Assays | 2013 |
Trichodermone, a spiro-cytochalasan with a tetracyclic nucleus (7/5/6/5) skeleton from the plant endophytic fungus Trichoderma gamsii.
Topics: Antineoplastic Agents; Cytochalasins; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Panax notoginseng; Trichoderma | 2014 |
Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
Topics: Antimitotic Agents; Benzophenones; Cell Line, Tumor; Cell Proliferation; Colchicine; Dose-Response Relationship, Drug; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; KB Cells; Molecular Structure; Polymerization; Structure-Activity Relationship; Tubulin | 2014 |
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzodioxoles; Caspase 3; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Glycosides; HT29 Cells; Humans; Lactones; Lignans; Mice; Molecular Structure; Naphthalenes; Nuclear Magnetic Resonance, Biomolecular; Phyllanthus; Vietnam | 2014 |
Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Heterocyclic Compounds, 4 or More Rings; Humans; MCF-7 Cells; Molecular Structure; Phenanthrolines; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2014 |
Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Intracellular Space; Poly(ADP-ribose) Polymerases; Proteolysis; Reactive Oxygen Species; Structure-Activity Relationship | 2014 |
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
Topics: Antineoplastic Agents; Capillaries; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Indoles; KB Cells; Mitosis; Molecular Structure; Polymerization; Structure-Activity Relationship; Sulfonamides; Tubulin; Tubulin Modulators | 2014 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Triphenylphosphonium Cations of the Diterpenoid Isosteviol: Synthesis and Antimitotic Activity in a Sea Urchin Embryo Model.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Cations; Disease Models, Animal; Diterpenes; Diterpenes, Kaurane; Humans; Mediterranean Sea; Mitochondria; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Organophosphorus Compounds; Sea Urchins; Structure-Activity Relationship | 2015 |
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
Topics: Angiogenesis Inhibitors; Antimitotic Agents; Benzene; Binding Sites; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Colchicine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Structure-Activity Relationship; Tubulin Modulators | 2015 |
Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
Topics: Antineoplastic Agents; Aryldialkylphosphatase; Electrophoresis, Polyacrylamide Gel; Humans | 2016 |
Anticancer activity studies of cubebin isolated from Piper cubeba and its synthetic derivatives.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Humans; Lignans; Models, Molecular; Neoplasms; Piper; Seeds | 2016 |
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; MCF-7 Cells; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship | 2016 |
Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Polymerization; Structure-Activity Relationship; Thiazoles; Triazoles; Tubulin | 2017 |
One-pot synthesis and biological evaluation of N-(aminosulfonyl)-4-podophyllotoxin carbamates as potential anticancer agents.
Topics: Antineoplastic Agents; Carbamates; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship | 2017 |
Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
Topics: Acetates; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Esters; Humans; MCF-7 Cells; Molecular Structure; Piperazine; Piperazines; Podophyllotoxin; Polymerization; Structure-Activity Relationship; Tubulin | 2017 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
Synthesis and biological evaluation of cyclopeptide GG-8-6 and its analogues as anti-hepatocellular carcinoma agents.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Peptides, Cyclic; Protein Structure, Tertiary; Structure-Activity Relationship; Transplantation, Heterologous | 2018 |
Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones.
Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Etoposide; Glycosides; Humans; Lactones; Lignans; Molecular Structure; Naphthalenes; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
In Vitro and in Vivo Antitumor Effects of Plant-Derived Miliusanes and Their Induction of Cellular Senescence.
Topics: Animals; Annonaceae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Cyclohexanols; Cyclohexanones; Female; Humans; Male; Mice, Inbred BALB C; Molecular Structure; Signal Transduction; Spiro Compounds; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Design, synthesis and evaluation of antiproliferative activity of fluorinated betulinic acid.
Topics: Betulinic Acid; Cell Proliferation; Humans; Molecular Structure; Pentacyclic Triterpenes; Triterpenes | 2019 |
Anti-cancer potential of novel glycosylated 1,4-substituted triazolylchalcone derivatives.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chalcone; Click Chemistry; Cycloaddition Reaction; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship | 2021 |
Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents.
Topics: Alkaloids; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Doxorubicin; Etoposide; Heart Rate; In Vitro Techniques; Microtubules; Myocardial Contraction; Nocodazole; Paclitaxel; Podophyllotoxin; Rats; Tubulin; Vinca Alkaloids | 1992 |
Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
Topics: Alkaloids; Animals; Antibodies, Monoclonal; Daunorubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Immunotoxins; Leukocyte Count; Mice; Mice, Transgenic; Paclitaxel; Pseudomonas aeruginosa; Vinblastine; Vincristine | 1992 |
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Ovarian Neoplasms; Paclitaxel; Rhodamines; Taxoids; Tumor Cells, Cultured | 1992 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Parenteral; Lymph Node Excision; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovariectomy; Paclitaxel | 1992 |
[Recent advances in ovarian cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
In vitro release of hydrophobic drugs from polyanhydride disks.
Topics: Alkaloids; Cell Division; Cells, Cultured; Decanoic Acids; Delayed-Action Preparations; Dicarboxylic Acids; Drug Implants; Etoposide; Fibroblasts; Floxuridine; Fluorouracil; Glaucoma; Humans; Mercaptopurine; Paclitaxel; Polymers; Postoperative Complications; Vincristine | 1991 |
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro.
Topics: Alkaloids; Cell Line; Colchicine; DNA; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; In Vitro Techniques; Maytansine; Microtubules; Paclitaxel; Podophyllotoxin; Time Factors; Vinblastine | 1987 |
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
Topics: Apoptosis; Calcimycin; Cell Cycle; Cell Survival; Child, Preschool; Cholera Toxin; Colforsin; DNA, Neoplasm; Enzyme Inhibitors; Ethers, Cyclic; Etoposide; Flow Cytometry; HL-60 Cells; Humans; Male; Mitosis; Nocodazole; Okadaic Acid; Paclitaxel; Phosphoprotein Phosphatases; Retinoblastoma; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured | 1995 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Clinical Protocols; Drug Resistance; Etoposide; Genetic Vectors; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Informed Consent; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancytopenia; Recombinant Fusion Proteins; Recombinant Proteins; Retroviridae; Stem Cell Factor; Transplantation, Autologous; Vinblastine | 1994 |
Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs.
Topics: Apoptosis; Cell Line; Centrosome; Etoposide; Methotrexate; Paclitaxel; RNA; Tubulin | 1995 |
In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.
Topics: Adenosine Triphosphate; Adult; Antineoplastic Agents; Choriocarcinoma; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Hydatidiform Mole; Paclitaxel; Pregnancy; Trophoblastic Neoplasms; Tumor Cells, Cultured; Uterine Neoplasms; Vincristine | 1995 |
Hypersensitivity reactions from taxol and etoposide.
Topics: Adult; Cross Reactions; Drug Hypersensitivity; Etoposide; Humans; Male; Paclitaxel | 1993 |
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine | 1994 |
Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA, Neoplasm; Doxorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Flow Cytometry; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1993 |
Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers.
Topics: Animals; Anterior Eye Segment; Drug Carriers; Drug Delivery Systems; Etoposide; Fibrosis; Glaucoma; Intraocular Pressure; Laser Therapy; Macaca fascicularis; Male; Paclitaxel; Polymers; Sclera; Sclerostomy | 1993 |
Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
Topics: Amsacrine; Animals; Biological Transport; Brefeldin A; Cell Survival; Cyclopentanes; DNA Damage; DNA Repair; Doxorubicin; Drug Synergism; Endoplasmic Reticulum; Etoposide; Golgi Apparatus; Kinetics; Leukemia L1210; Mice; Microtubules; Nocodazole; Paclitaxel; Temperature; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
Topics: Cholestasis; Doxorubicin; Drug Resistance; Estradiol; Estriol; Etoposide; Humans; Leukemia, Myeloid; Paclitaxel; Sarcoma; Tumor Cells, Cultured; Vinblastine | 1993 |
Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Count; Cell Line; Cell Nucleus; Cells, Cultured; Etoposide; Fluorescent Antibody Technique; G2 Phase; HeLa Cells; Humans; Kinetics; Mice; Mitosis; Paclitaxel; Phenotype; Prophase; Rats; Tubulin; Tumor Suppressor Protein p53 | 1995 |
Genetic toxicity in relation to receptor-mediated carcinogenesis.
Topics: Aniline Compounds; Animals; Carcinogens; Etoposide; Humans; Mutagens; Paclitaxel; Receptors, Cell Surface | 1995 |
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 1996 |
Effects of Taxol on choriocarcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Choriocarcinoma; Chorionic Gonadotropin; Cycloheximide; Etoposide; Female; Humans; Methotrexate; Paclitaxel; Pregnancy; Tumor Cells, Cultured; Uterine Neoplasms | 1995 |
Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
Topics: Antineoplastic Agents; Doxorubicin; Drug Resistance, Multiple; Etoposide; Guanidines; Humans; Paclitaxel; Polymers; Sarcoma; Spermine; Tumor Cells, Cultured; Vinblastine | 1996 |
Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; B-Lymphocytes; Biological Transport; Burkitt Lymphoma; Calcium Channel Blockers; Cell Adhesion Molecules; Chloroquine; Colchicine; Etoposide; Humans; Immunoglobulin Isotypes; Immunotoxins; Iodine Radioisotopes; Lectins; Leukemia, B-Cell; Mice; Monensin; Paclitaxel; Radioimmunotherapy; Receptors, IgG; Sialic Acid Binding Ig-like Lectin 2; Verapamil; Vinblastine; Vincristine | 1996 |
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 1996 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia | 1996 |
Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Tritium; Tumor Cells, Cultured | 1996 |
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Cells, Cultured; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Rats | 1996 |
Chemotherapy enhancer passes first test.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Neoplasms; Paclitaxel | 1995 |
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1996 |
Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Membrane; Cell Survival; Dibenzocycloheptenes; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Leukemia P388; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Protein Binding; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine | 1996 |
Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured | 1996 |
An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo.
Topics: Animals; Apoptosis; Carmustine; Colonic Neoplasms; DNA Fragmentation; Doxorubicin; Etoposide; Mice; Paclitaxel; Photochemotherapy; Protoporphyrins | 1996 |
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carboplatin; Cell Cycle; Cell Line; Cell Survival; Etoposide; Female; Humans; Hydroxyurea; Immunoblotting; Kinetics; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53; Vincristine | 1996 |
Extended multidrug resistance in haemopoietic cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Interactions; Etoposide; Fluorouracil; Mice; Mice, Inbred C3H; Paclitaxel; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1997 |
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Topics: Antineoplastic Agents; Cisplatin; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Female; Glutathione; Humans; Mitomycin; Ovarian Neoplasms; Paclitaxel; Regression Analysis; Tumor Cells, Cultured | 1997 |
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
Topics: Adenosine Triphosphatases; Affinity Labels; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Heat-Shock Proteins; Humans; Mice; Paclitaxel; Piperidines; Pyridines; Tacrolimus Binding Proteins; Transfection; Tumor Cells, Cultured; Vincristine | 1997 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 1997 |
Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells.
Topics: Affinity Labels; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Membrane; Chromatography, High Pressure Liquid; Cyclosporine; Dihydropyridines; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Etoposide; Humans; Hydroxylation; Kinetics; Methylation; Molecular Structure; Paclitaxel; Photochemistry; Tumor Cells, Cultured | 1997 |
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay | 1997 |
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle; Cell Survival; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Polymerase Chain Reaction; Rhodamines; Stomach Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carrier Proteins; Cell Survival; Chromosome Mapping; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Cisplatin; Colonic Neoplasms; DNA Repair; Drug Resistance, Multiple; Etoposide; Humans; Mutagenesis; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Repetitive Sequences, Nucleic Acid; Tumor Cells, Cultured | 1997 |
A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cloning, Molecular; Drug Resistance, Multiple; Etoposide; Folic Acid Antagonists; Gene Expression; Genetic Vectors; Hematopoietic Stem Cells; Humans; Methotrexate; Paclitaxel; Proviruses; Retroviridae; Tetrahydrofolate Dehydrogenase; Transformation, Genetic; Trimetrexate; Tumor Cells, Cultured; Vinblastine | 1997 |
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Proteins; Carcinoma, Small Cell; Chlorambucil; Cisplatin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; RNA, Messenger; Serine Endopeptidases; Tumor Cells, Cultured; Vinblastine | 1998 |
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carboplatin; Cell Line; Cell Survival; Cisplatin; Cricetinae; Cricetulus; Daunorubicin; Doxorubicin; Drug Screening Assays, Antitumor; Electroporation; Etoposide; Lung; Paclitaxel | 1998 |
A unique interaction between polyamine and multidrug resistance (P-glycoprotein) transporters in cultured Chinese hamster ovary cells transfected with mouse mdr-1 gene.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; CHO Cells; Cricetinae; Cricetulus; Doxorubicin; Etoposide; Flow Cytometry; Mice; Paclitaxel; Protein Binding; Spermidine; Transfection | 1998 |
"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; bcl-X Protein; Binding Sites; Blotting, Western; Cytarabine; Cytochrome c Group; Cytosol; DNA, Neoplasm; Etoposide; HL-60 Cells; Humans; Mutation; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Conformation; Protein Structure, Tertiary; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection | 1998 |
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured | 1998 |
Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Role of E2F-1 in chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Etoposide; HL-60 Cells; Humans; Paclitaxel; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 1998 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured | 1997 |
Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation; Genetic Vectors; HeLa Cells; Humans; Methylnitronitrosoguanidine; Mice; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Prohibitins; Recombinant Proteins; Retroviridae; Transfection; Vincristine | 1997 |
Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cytarabine; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, jun; HL-60 Cells; Humans; Leukemia, B-Cell; Mitoxantrone; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1995 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Indirect-response model for the time course of leukopenia with anticancer drugs.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Mathematical Computing; Middle Aged; Models, Theoretical; Paclitaxel; Time Factors | 1998 |
Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Fenretinide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1999 |
Hepatic artery administration of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cimetidine; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Etoposide; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication | 1999 |
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitrosourea Compounds; Paclitaxel; Vinblastine | 1998 |
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 1999 |
Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cisplatin; Cladribine; Drug Screening Assays, Antitumor; Etoposide; Humans; Lymphoma, B-Cell; Paclitaxel; Tumor Cells, Cultured | 1999 |
Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents.
Topics: Apoptosis; Cell Line; Cytarabine; DNA Damage; Enzyme Activation; Etoposide; Humans; Hydrolysis; MAP Kinase Kinase Kinase 1; Microtubules; Mutagens; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Vinblastine | 1999 |
Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NfkappaB-dependent mechanism.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Differentiation; Cell Line; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoplasm; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Etoposide; Extracellular Matrix; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Nucleic Acid Synthesis Inhibitors; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Tetrazolium Salts; Thiazoles; Time Factors; Transfection | 1999 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine | 1999 |
Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; Etoposide; Flow Cytometry; HeLa Cells; Humans; Mitochondria; Paclitaxel | 1999 |
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cisplatin; DNA Fragmentation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Taxoids; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 1999 |
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
Topics: Animals; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Caco-2 Cells; Cattle; Contrast Media; Doxorubicin; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Etoposide; Excipients; Fluorescein; Humans; Intestinal Absorption; Loperamide; Micelles; Microcirculation; Paclitaxel; Poloxamer; Tritium; Valproic Acid; Zidovudine | 1999 |
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1999 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Clinical Protocols; Decision Making; Diagnostic Imaging; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy, Adjuvant; United States | 2000 |
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
Topics: Animals; Antineoplastic Agents; Cell Survival; Ceramides; Cyclosporins; Drug Synergism; Enzyme Inhibitors; Etoposide; Glucosyltransferases; Morpholines; Neuroblastoma; Paclitaxel; Tumor Cells, Cultured; Vincristine | 2000 |
The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Caspase 3; Caspase 8; Caspase 9; Caspases; Cytochrome c Group; Cytosol; Enzyme Precursors; Etoposide; Fibroblasts; Gene Expression Regulation; HL-60 Cells; Humans; Intracellular Membranes; Membrane Potentials; Mice; Mitochondria; Paclitaxel; Proteins; Recombinant Fusion Proteins | 2000 |
Doxazosin: a new cytotoxic agent for prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxazosin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids | 2000 |
Management of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Survival; Ceramides; Colchicine; Colonic Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; Galactosylceramides; Glucosylceramides; HT29 Cells; Humans; Immunoblotting; Immunohistochemistry; Microscopy, Confocal; Microtubules; Mitosis; Multidrug Resistance-Associated Proteins; Paclitaxel; Propionates; Quinolines; Signal Transduction; Sphingolipids; Vincristine | 2000 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Multidrug Resistance-Associated Proteins; Mutation; Neoplasm Proteins; Paclitaxel; Phenotype; Rhodamine 123; RNA, Messenger; Sarcoma; Tritium; Tumor Cells, Cultured; Uterine Neoplasms; Vault Ribonucleoprotein Particles; Vinblastine | 2000 |
Mobilization and transplantation of peripheral blood stem cells.
Topics: Antigens, CD34; Blood Transfusion; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Cytokines; Erythrocytes; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Paclitaxel; Platelet Transfusion; Regression Analysis; Retrospective Studies; Transplantation, Autologous | 1998 |
An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carmustine; Equipment Design; Etoposide; Gloves, Protective; Humans; Latex; Nitriles; Occupational Exposure; Paclitaxel; Permeability; Time Factors | 1999 |
[Roles of p53 in chemotherapy of glioblastoma].
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cisplatin; Etoposide; Flow Cytometry; Glioblastoma; Nimustine; Paclitaxel; Polymerase Chain Reaction; Temperature; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Carcinoma of unknown primary site.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2000 |
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine | 2001 |
DNase I mediates internucleosomal DNA degradation in human cells undergoing drug-induced apoptosis.
Topics: Apoptosis; Cell Nucleus; Cell Survival; Cycloheximide; Dactinomycin; Deoxyribonuclease I; DNA; DNA Fragmentation; Etoposide; fas Receptor; Gene Targeting; Humans; Jurkat Cells; Kinetics; Nucleosomes; Paclitaxel; Transfection; Tumor Cells, Cultured | 2001 |
Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells.
Topics: Amino Acid Sequence; Animals; Antibodies; Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Cytochrome c Group; Erythrocytes; Etoposide; HeLa Cells; Humans; Ion Channels; Mammals; Membrane Proteins; Mitochondria; Mitochondria, Liver; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Porins; Protein Conformation; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred Strains; Recombinant Proteins; Staurosporine; Transfection; Voltage-Dependent Anion Channels | 2001 |
Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Calcium-Binding Proteins; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cyclin B; Cyclin B1; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Antagonism; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Etoposide; Flow Cytometry; Fungal Proteins; Humans; Nasopharyngeal Neoplasms; Nuclear Proteins; Paclitaxel; Precipitin Tests; Protein Kinases; Tetrazolium Salts; Thiazoles; Toxicity Tests; Tumor Cells, Cultured | 2001 |
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan | 2001 |
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles | 2001 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms; Colony-Forming Units Assay; Cricetinae; Drug Screening Assays, Antitumor; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Thymidine; Tritium; Tumor Cells, Cultured | 2001 |
PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells.
Topics: Adenoviridae; Animals; Apoptosis; Blotting, Western; Brefeldin A; Caspase 3; Caspase 9; Caspases; Cell Line; Cell Separation; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Etoposide; Flow Cytometry; Genes, Dominant; Isoenzymes; Lac Operon; Mitochondria; Mutation; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Isoforms; Protein Kinase C; Protein Kinase C-delta; Protein Synthesis Inhibitors; Radiation-Sensitizing Agents; Rats; Salivary Glands; Time Factors; Ultraviolet Rays | 2001 |
Using solution phase hydrogen/deuterium (H/D) exchange to determine the origin of non-covalent complexes observed by electrospray ionization mass spectrometry: in solution or in vacuo?
Topics: Algorithms; Antineoplastic Agents; Deuterium; Doxorubicin; Etoposide; Hydrogen; Molecular Weight; Paclitaxel; Spectrometry, Mass, Electrospray Ionization | 2001 |
Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bleomycin; Cells, Cultured; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Endothelium, Vascular; Etoposide; Glutathione; Humans; Immunohistochemistry; L-Lactate Dehydrogenase; Malondialdehyde; Necrosis; Oxidative Stress; Paclitaxel; Peptidyl-Dipeptidase A; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Umbilical Veins | 2001 |
Paclitaxel and lung cancer: new preparation. No therapeutic progress.
Topics: Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Teniposide; Treatment Outcome | 2000 |
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Fluorouracil; Imidazoles; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred BALB C; Paclitaxel; Quinolines; Tirapazamine; Triazines; Tumor Cells, Cultured | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I-infected T-cells from apoptosis by the viral tax protein.
Topics: Antineoplastic Agents; Apoptosis; Carcinogens; Cell Line; Cisplatin; Etoposide; Gene Expression Regulation; Gene Products, tax; Genes, Reporter; Human T-lymphotropic virus 1; Humans; Methylcholanthrene; Paclitaxel; Protein Isoforms; Protein Kinase C; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes; Terminal Repeat Sequences; Tetracycline; Tetradecanoylphorbol Acetate; Transfection | 2001 |
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA Repair; Doxorubicin; Doxycycline; Enzyme Inhibitors; Etoposide; Flow Cytometry; G2 Phase; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Topoisomerase I Inhibitors; Topotecan | 2002 |
Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.
Topics: Acute Disease; Adult; Antigens, CD34; Blood Cell Count; Blood Component Removal; Blood Platelets; Cyclophosphamide; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Multiple Myeloma; Paclitaxel; Prospective Studies; Recombinant Proteins; Transplantation, Autologous | 2001 |
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
Topics: Antineoplastic Agents; Cell Division; Cyanides; Etoposide; Guanidines; Humans; Paclitaxel; Time Factors; Topotecan; Tumor Cells, Cultured | 2001 |
Effect of mesna on lethal effect and hematological toxicity of taxol and vepeside in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Male; Mesna; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Paclitaxel; Protective Agents; Time Factors | 2001 |
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Doxorubicin; Esophagogastric Junction; Etoposide; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Stomach Neoplasms | 2001 |
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Carboplatin; Carotid Arteries; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dacarbazine; Etoposide; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Physical Examination; Rupture, Spontaneous; Temozolomide; Temporal Lobe; Vertebral Artery | 2001 |
Chemotherapy and pregnancy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etoposide; Germinoma; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2001 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Caspase Inhibitors; Caspases; Cell Fractionation; Ceramides; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Isoenzymes; Male; Mitochondria; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Signal Transduction; Sphingomyelins; Tumor Cells, Cultured | 2002 |
Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chromosome Aberrations; Chromosomes, Human, Pair 12; Diagnosis, Differential; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Paclitaxel; Pelvic Neoplasms; Seminoma | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; beta-Galactosidase; Blotting, Western; Caspases; DNA Primers; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fibroblasts; Humans; I-kappa B Proteins; Luciferases; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Etoposide; G1 Phase; Humans; Insulin-Like Growth Factor Binding Protein 3; Paclitaxel; Resting Phase, Cell Cycle; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
Topics: Animals; Antibody Specificity; Antineoplastic Agents; Antioxidants; Cysteine; Doxorubicin; Etoposide; Humans; Hydrogen Peroxide; Immune Sera; Male; Mice; Oxidative Stress; Paclitaxel; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Prostatic Neoplasms; Protein Isoforms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2002 |
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carrier Proteins; Caspase 3; Caspase 7; Caspase 9; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Peptides; Protein Binding; Protein Structure, Tertiary; Proteins; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2002 |
The role of MAPK pathways in the action of chemotherapeutic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine | 2002 |
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Paclitaxel; Prednisone; Rituximab; Time Factors; Topotecan; Treatment Outcome; Vincristine | 2002 |
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Chromones; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Flow Cytometry; Humans; Immunoblotting; Morpholines; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tamoxifen; Time Factors; Transfection; Trastuzumab; Tumor Cells, Cultured | 2002 |
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine | 2002 |
Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death.
Topics: Alu Elements; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Brain; Cell Death; Cells, Cultured; DNA Transposable Elements; Etoposide; Exons; HeLa Cells; Humans; Lymph Nodes; Molecular Sequence Data; Myocardium; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; RNA Splicing | 2003 |
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured | 2003 |
In regard to hyperfractionation for non-small-cell lung cancer: fire, ready, aim!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic | 2003 |
Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Caveolin 1; Caveolin 2; Caveolins; Cell Cycle; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; Paclitaxel; RNA, Messenger; Up-Regulation | 2003 |
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Division; Cell Line, Transformed; Cyclin-Dependent Kinases; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Head and Neck Neoplasms; Humans; Interleukin-2 Receptor alpha Subunit; Janus Kinase 3; Multienzyme Complexes; Paclitaxel; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin; Tumor Cells, Cultured; Ubiquitin | 2003 |
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; Enzyme Inhibitors; Etoposide; Glioma; Humans; Microtubules; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Tumor Cells, Cultured; Vincristine | 2003 |
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Epstein-Barr Virus Nuclear Antigens; Etoposide; Female; G2 Phase; Genetic Therapy; Humans; Kinetics; Mitosis; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2003 |
Chemotherapy and antiangiogenesis--drug-specific, dose-related effects.
Topics: Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Endothelial Growth Factors; Etoposide; Fluorouracil; Humans; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mesentery; Methotrexate; Neovascularization, Physiologic; Paclitaxel; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Weight Gain | 2003 |
Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glutathione; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2003 |
Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Rate; Uterine Cervical Neoplasms | 2003 |
Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspases; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine; Vincristine; Xenograft Model Antitumor Assays | 2003 |
Caspase-3-mediated cleavage of Cdc6 induces nuclear localization of p49-truncated Cdc6 and apoptosis.
Topics: Active Transport, Cell Nucleus; Amino Acid Motifs; Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Membrane; Cell Nucleus; Cyclin-Dependent Kinase 2; DNA Replication; Etoposide; Flow Cytometry; Ginsenosides; HeLa Cells; Humans; Membrane Glycoproteins; Nuclear Localization Signals; Paclitaxel; Phosphorylation; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cisplatin; DNA Damage; Etoposide; G2 Phase; Humans; Microtubules; Mitosis; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Topotecan as first-line therapy for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan | 2003 |
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Body Weight; Bombesin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cell Division; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Humans; Immunotherapy; Interferon-gamma; Lung Neoplasms; Mice; Mice, SCID; Models, Chemical; Monocytes; Neoplasm Transplantation; Paclitaxel; Protein Binding; Receptors, Bombesin; Thymidine | 2003 |
Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2003 |
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Paclitaxel | 2004 |
Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Separation; Cell Survival; Cells, Cultured; Coloring Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Heart Neoplasms; Histiocytoma, Benign Fibrous; Humans; Inhibitory Concentration 50; Paclitaxel; Phenotype; Plant Extracts; Soft Tissue Neoplasms; Tetrazolium Salts; Thiazoles; Vault Ribonucleoprotein Particles; Vincristine | 2004 |
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan | 2004 |
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorouracil; Humans; Mice; Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Spheroids, Cellular; Vinblastine | 2004 |
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Blotting, Western; Carcinoma, Small Cell; Caspase 3; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Immunoblotting; Lung Neoplasms; Membrane Potentials; Mitochondria; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2004 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Necrosis; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Testicular Neoplasms | 2004 |
Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Salvage Therapy; Uterine Neoplasms | 2004 |
Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; cdc25 Phosphatases; Cell Cycle; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Cyclin E; DNA; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Kinetics; Osteosarcoma; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Ultraviolet Rays | 2005 |
[Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2004 |
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Follow-Up Studies; Germany; Germinoma; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Testicular Neoplasms; Translocation, Genetic; Transplantation, Autologous | 2005 |
Differential effects of RhoA signaling on anticancer agent-induced cell death.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Death; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Lovastatin; Paclitaxel; rhoA GTP-Binding Protein; Signal Transduction; Transfection; Tumor Cells, Cultured; Vincristine | 2005 |
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.
Topics: Animals; Antineoplastic Agents; Calotropis; Camptothecin; Cardenolides; Cell Line, Tumor; Cell Proliferation; Cerebral Cortex; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Maximum Tolerated Dose; Mice; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Swine; Thiazoles | 2005 |
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
Sensitization for anticancer drug-induced apoptosis by betulinic Acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Caspases; Cells, Cultured; Cisplatin; Complement Membrane Attack Complex; Complement System Proteins; Cytochromes c; Dactinomycin; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Fibroblasts; Glycoproteins; Humans; Membrane Potentials; Mitochondria; Mutation; Neoplasms; Paclitaxel; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2005 |
Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
Topics: Aphidicolin; Camptothecin; Cell Cycle; Cell Division; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; G2 Phase; HIV; HIV Infections; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Time Factors; Transduction, Genetic; Virus Replication | 2005 |
Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents.
Topics: Anoikis; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Extracellular Matrix; Flow Cytometry; Humans; Hypoxia; Neoplasm Metastasis; Osteosarcoma; Paclitaxel; Propidium; Vinblastine | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Docetaxel; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Probenecid; Taxoids; Vinblastine | 2005 |
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Docetaxel; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Sex Cord-Gonadal Stromal Tumors; Taxoids | 2005 |
Cytogenetic damage in lymphocytes of patients undergoing therapy for small cell lung cancer and ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Lymphocytes; Male; Micronuclei, Chromosome-Defective; Micronucleus Tests; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Boron Compounds; Brain; Cattle; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclosporine; Deoxyglucose; Drug Screening Assays, Antitumor; Endocytosis; Endothelium, Vascular; Etoposide; Lactic Acid; Microspheres; Nanotubes; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2005 |
Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis.
Topics: Amaryllidaceae Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Etoposide; Fibroblasts; Humans; Intracellular Membranes; Isoquinolines; Mitochondria; Neuroblastoma; Paclitaxel; Permeability; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Tumor Cells, Cultured | 2005 |
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Painting; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Infusions, Intravenous; Macaca mulatta; Neutropenia; Paclitaxel; Thiotepa | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gemcitabine; Genes, Tumor Suppressor; Humans; Mutation, Missense; Nuclear Proteins; Paclitaxel; Plasmids; Polymorphism, Genetic; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vinblastine | 2005 |
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha | 2005 |
Detection of numerical chromosomal aberrations by flow cytometry: a novel process for identifying aneugenic agents.
Topics: Adult; Aneugens; Cells, Cultured; Chromosome Aberrations; Etoposide; Female; Flow Cytometry; Griseofulvin; Humans; Lymphocytes; Male; Mitomycin; Mitosis; Mutagenicity Tests; Paclitaxel; Polyploidy | 2005 |
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Creatinine; Cyclophosphamide; Decision Making; Etoposide; Female; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Platelet Count; Survival Rate; Treatment Outcome | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin.
Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Humans; Isoquinolines; Neoplasms; Paclitaxel; Rats | 2005 |
Prophylactic cranial irradiation in limited-stage small-cell lung cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Hospitals, Community; Humans; Lung Neoplasms; Male; Middle Aged; North Dakota; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Treatment Refusal | 2004 |
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Etoposide; Female; Gastrectomy; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
[International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Etoposide; Humans; Internationality; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Randomized Controlled Trials as Topic; Testicular Neoplasms; Treatment Outcome | 2005 |
Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Sensitivity and Specificity; Trastuzumab; Tumor Cells, Cultured | 2006 |
Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vinblastine | 2006 |
Metastatic choriocarcinoma successfully treated with paclitaxel and carboplatin after interstitial lung disease induced by EMA-CO.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Methotrexate; Paclitaxel; Uterine Neoplasms; Vincristine | 2006 |
Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
[Current data concerning neoadjuvant chemotherapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Ifosfamide; Lung; Lung Neoplasms; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk; Time Factors | 2006 |
Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta; Cell Proliferation; Cells, Cultured; Etoposide; Fibroblasts; Humans; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Paclitaxel; Proto-Oncogene Proteins c-akt; Saphenous Vein; Tubulin Modulators | 2006 |
Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain-Derived Neurotrophic Factor; Cell Death; Cisplatin; Down-Regulation; Enzyme Activation; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Membrane Proteins; Mitogen-Activated Protein Kinases; Molecular Mimicry; Neuroblastoma; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins; Receptor, trkB; RNA, Messenger; RNA, Small Interfering | 2007 |
Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Pleural Diseases; Pneumonectomy; Pneumonia; Pneumonia, Aspiration; Postoperative Complications; Pulmonary Embolism; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Tract Fistula; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Fluorescent Antibody Technique; Humans; Immunoblotting; Immunoprecipitation; Ovarian Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2006 |
Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Etoposide; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Muscle Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Time Factors | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
[A non-seminomatous extra-gonadal germ cell tumor responding to intensive treatment: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retroperitoneal Neoplasms | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan | 2006 |
DNA cleavage and Trp53 differentially affect SINE transcription.
Topics: Antineoplastic Agents; Cisplatin; DNA Cleavage; DNA Damage; Etoposide; Genomic Instability; Humans; Paclitaxel; Short Interspersed Nucleotide Elements; Thiobarbiturates; Topoisomerase II Inhibitors; Transcription, Genetic; Tumor Suppressor Protein p53; Up-Regulation; Vincristine | 2007 |
Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.
Topics: Amino Acid Chloromethyl Ketones; Amsacrine; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Paclitaxel; Reactive Oxygen Species; Topoisomerase II Inhibitors; Tubulin Modulators; Vinblastine | 2006 |
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Etoposide; Fluorouracil; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Catalytic; Stathmin | 2006 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine | 2007 |
Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Capsid Proteins; Cell Line, Tumor; Cell Survival; DNA, Viral; Drug Synergism; Etoposide; Genetic Vectors; Humans; Paclitaxel; Transfection | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Topics: Anthracyclines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Survival; Cisplatin; Colchicine; Cytoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Female; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Membrane Potentials; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Phenotype | 2007 |
Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma.
Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Combined Chemotherapy Protocols; Corticotropin-Releasing Hormone; Cushing Syndrome; Duodenal Neoplasms; Etoposide; Female; Gastrinoma; Humans; Hydrocortisone; Liver Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2007 |
Poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles.
Topics: Acetates; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Compounding; Emulsifying Agents; Etoposide; Freeze Drying; Kinetics; Lactates; Magnesium Chloride; Methylene Chloride; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polystyrenes; Polyvinyls; Solubility; Solvents; Technology, Pharmaceutical; Water | 2007 |
[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Topics: Adult; Antineoplastic Agents; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Bcl-2 gene silencing in pediatric epithelial liver tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Child; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelium; Etoposide; Gene Silencing; Genetic Therapy; Humans; Liver Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection | 2008 |
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate | 2007 |
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Butylated Hydroxytoluene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Paclitaxel; Permeability; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides | 2007 |
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation; Humans; Paclitaxel; T-Lymphocytes | 2008 |
Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; CDC2 Protein Kinase; Cells, Cultured; DNA Primers; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Immunoblotting; Keratinocytes; Oncogene Proteins, Viral; Paclitaxel; Proteomics; Repressor Proteins; RNA, Small Interfering; Transformation, Genetic; Tumor Suppressor Protein p53 | 2007 |
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2008 |
Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Cyclophosphamide; Doxorubicin; Drug Synergism; Etoposide; Gossypol; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisolone; Tumor Suppressor Protein p53; Vincristine | 2008 |
Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Korea; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Salvage Therapy; Severity of Illness Index; Uterine Neoplasms | 2007 |
The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Humans; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Secondary Prevention; Testicular Neoplasms; Treatment Outcome | 2007 |
Germ-cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Salvage Therapy; Testicular Neoplasms | 2007 |
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome | 2007 |
Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Etoposide; Humans; Lipids; Microscopy, Confocal; Nanocapsules; Paclitaxel | 2007 |
Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic HL-60 cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cisplatin; Etoposide; Glutathione; HL-60 Cells; Humans; Leukemia; Membrane Potential, Mitochondrial; Ornithine Decarboxylase; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Putrescine; Reactive Oxygen Species | 2008 |
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Premedication; Retrospective Studies; Transplantation, Autologous | 2008 |
Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis | 2008 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Calcium-Binding Proteins; Cell Proliferation; Epirubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cathepsin D; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Immunoblotting; Lysosomes; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Ovarian Neoplasms; Paclitaxel; Protein Transport; RNA Interference; Signal Transduction | 2009 |
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2008 |
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2008 |
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine | 2009 |
Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; RNA, Messenger | 2008 |
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Infusions, Parenteral; Interferon alpha-2; Interferon-alpha; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Retrospective Studies; Survival Analysis; Thiotepa | 2009 |
Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Cisplatin; Cluster Analysis; DNA Adducts; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Gene Expression Regulation; Humans; Laboratories; Mutagenicity Tests; Mutagens; Observer Variation; Paclitaxel; Polymerase Chain Reaction; Reproducibility of Results; Risk Assessment; Sodium Chloride; Spindle Apparatus; Time Factors | 2009 |
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured; X-Rays | 2009 |
The stage of offspring of female rats after treatment with cytostatics of various groups.
Topics: Animals; Carboplatin; Cisplatin; Cytostatic Agents; Drug Administration Schedule; Epirubicin; Etoposide; Female; Male; Paclitaxel; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Time Factors | 2008 |
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Pulmonary Diffusing Capacity; Radiotherapy Dosage; Retrospective Studies | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; STAT5 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Drosophila Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Fibroblasts; Heat-Shock Proteins; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondrial Proteins; Neoplasms, Experimental; Nocodazole; Paclitaxel; Transfection; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2010 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
[Case of far-advanced retroperitoneal extra-gonadal germ cell tumor responding to intensive treatment including multi-drug chemotherapy with peripheral blood stem cell transplantation and residual tumor removal].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Lymph Node Excision; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retroperitoneal Neoplasms; Treatment Outcome | 2010 |
Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Genistein; Humans; Lung Neoplasms; Paclitaxel; Tumor Suppressor Protein p53 | 2010 |
Discovering breast cancer drug candidates from biomedical literature.
Topics: Antineoplastic Agents; Breast Neoplasms; Data Mining; Doxorubicin; Drug Discovery; Etoposide; Female; Humans; Internet; MEDLINE; Paclitaxel; Publications | 2010 |
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; Male; MicroRNAs; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Tumor Suppressor Protein p53 | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells.
Topics: Breast Neoplasms; Cell Fusion; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; Etoposide; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Humans; Hybrid Cells; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide for patients with relapsed primary mediastinal nonseminomatous germ cell tumors: benefit from chemotherapy, surgery, or both?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Mediastinal Neoplasms; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Testicular Neoplasms | 2010 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation.
Topics: Autophagy; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; DNA Fragmentation; DNA Replication; Etoposide; Gamma Rays; Genome, Human; Homeodomain Proteins; Humans; Mitosis; Nanog Homeobox Protein; Neoplasms; Octamer Transcription Factor-3; Paclitaxel; Ploidies; Tumor Suppressor Protein p53 | 2011 |
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Databases, Factual; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Thiotepa; Vinblastine; Young Adult | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2011 |
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome | 2011 |
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Fertility sparing surgery for ovarian tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Fertility Preservation; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Ovarian Cysts; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prospective Studies; Young Adult | 2012 |
Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Etoposide; Fluorescent Antibody Technique; Humans; Hyaluronan Receptors; Immunoblotting; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Retinoblastoma-Binding Protein 2; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine | 2011 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration | 2011 |
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
Topics: Animals; Antineoplastic Agents; Cathepsins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Lung Neoplasms; Macrophages; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasm Invasiveness; Paclitaxel | 2011 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Muscle Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors | 2012 |
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Cell Differentiation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fluorescent Antibody Technique, Indirect; Humans; Mesenchymal Stem Cells; Neoplasm Proteins; Neoplastic Stem Cells; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms | 2012 |
Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Etoposide; fas Receptor; Humans; Osteosarcoma; Paclitaxel; Temperature | 2012 |
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Keratinocytes; Liver Neoplasms; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cholesterol, LDL; Drug Delivery Systems; Etoposide; Fat Emulsions, Intravenous; Female; Flow Cytometry; Injections, Intraperitoneal; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Paclitaxel | 2012 |
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Movement; Cisplatin; Cytoskeleton; Etoposide; Guanine Nucleotide Exchange Factors; Humans; Myosin Light Chains; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Stomach Neoplasms; Vincristine | 2012 |
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cardiovascular Diseases; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Quality of Life; Stem Cell Transplantation; Surveys and Questionnaires; Survivors; Treatment Outcome; Young Adult | 2013 |
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma | 2013 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine | 2012 |
The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Etoposide; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Retrospective Studies; Societies, Medical; Survival Rate; United States | 2013 |
Treatment update in small-cell lung cancer: from limited to extensive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan | 2012 |
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types.
Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; DNA Damage; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2012 |
Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Neuroendocrine; Cystectomy; Etoposide; Female; Gallbladder Neoplasms; Hepatectomy; Humans; Immunohistochemistry; Liver Neoplasms; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasms, Complex and Mixed; Octreotide; Paclitaxel; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2013 |
Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thoracic Surgical Procedures; Time Factors; Treatment Outcome; Young Adult | 2014 |
Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Etoposide; Fluorouracil; Hodgkin Disease; Humans; Interleukin-13; Interleukin-4; Mitomycin; Paclitaxel; Promoter Regions, Genetic; Reed-Sternberg Cells; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT6 Transcription Factor | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
[Neuroendocrine tumors: analysis of 252 cases].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Cisplatin; Digestive System Neoplasms; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Retrospective Studies; Sex Factors; Survival Rate; Young Adult | 2013 |
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Review Literature as Topic | 2013 |
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2013 |
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Furans; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, SCID; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitotane; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil | 2013 |
Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Uterine Cervical Neoplasms; Young Adult | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53 | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
The predominant role of apoptosis in γH2AX formation induced by aneugens is useful for distinguishing aneugens from clastogens.
Topics: Aneugens; Apoptosis; Cells, Cultured; DNA Damage; Etoposide; Histones; Humans; Micronucleus Tests; Mitomycin; Mutagens; Paclitaxel; Vinblastine | 2014 |
Attempted conservative management of a placental site trophoblastic tumor: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lymph Node Excision; Methotrexate; Paclitaxel; Pregnancy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms; Vincristine | 2014 |
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2015 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2015 |
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib | 2015 |
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Histiocytic Sarcoma; Melphalan; Methotrexate; Nimustine; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vincristine | 2015 |
Education and imaging. Gastrointestinal: Gastric involvement in disseminated lymphadenopathic Kaposi sarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Doxorubicin; Endoscopy, Digestive System; Etoposide; Humans; Interferons; Male; Paclitaxel; Palliative Care; Sarcoma, Kaposi; Stomach Neoplasms | 2015 |
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Topics: Animals; Apoptosis; Binding Sites; Binding, Competitive; Carbolines; Cell Line, Tumor; Colchicine; Colonic Neoplasms; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Superhelical; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Metaphase; Mice; Mice, Nude; Microtubules; Molecular Structure; Neoplasm Proteins; Paclitaxel; Topoisomerase II Inhibitors; Tubulin; Tubulin Modulators; Vincristine | 2015 |
Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Carriers; Etoposide; Humans; Lactic Acid; Nanoparticles; Osteosarcoma; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Camptothecin; Cisplatin; Etoposide; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retreatment; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia | 2017 |
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Hepatic Insufficiency; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms; Vincristine | 2015 |
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 2015 |
MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Breast; Cadherins; Cell Line, Transformed; Colchicine; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; E1A-Associated p300 Protein; Epithelial Cells; Etoposide; Gamma Rays; Humans; MicroRNAs; Multigene Family; Neoplasm Proteins; Paclitaxel; Phenotype; RNA, Neoplasm; Transduction, Genetic; Tumor Stem Cell Assay | 2016 |
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2016 |
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2016 |
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2016 |
α-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin β1/β3 downregulation.
Topics: Anoikis; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Drug Therapy; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Integrin beta3; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Reactive Oxygen Species; Thioctic Acid | 2016 |
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.
Topics: Amines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Interactions; Etoposide; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Nude; Micelles; N-Acetylneuraminic Acid; Nanoparticles; Paclitaxel; Particle Size; Solubility; Surface Properties; Surface-Active Agents | 2016 |
A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Guillain-Barre Syndrome; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Paraplegia; Spinal Cord Neoplasms; Tomography, X-Ray Computed | 2016 |
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms | 2017 |
Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Ependymoma; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Treatment Outcome; Young Adult | 2016 |
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Etoposide; Fatal Outcome; Genomics; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Paclitaxel; Rare Diseases; Scalp; Xenograft Model Antitumor Assays | 2016 |
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Etoposide; Feasibility Studies; Female; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Respiratory Insufficiency; Retrospective Studies; Tegafur | 2017 |
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fluid Therapy; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Rhabdomyolysis; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
Induced Aneugenic Effects in Mouse Oocytes In Vivo.
Topics: Aneugens; Aneuploidy; Animals; Cisplatin; Colchicine; Doxorubicin; Etoposide; Melphalan; Mice; Oocytes; Paclitaxel; Polyploidy | 2017 |
Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Etoposide; Humans; Nanoparticles; Osteosarcoma; Paclitaxel; Polymers | 2017 |
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2017 |
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis | 2017 |
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2017 |
Simultaneous LC-MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self-microemulsifying drug-delivery systems.
Topics: Administration, Oral; Animals; Chromatography, Liquid; Drug Delivery Systems; Drug Stability; Emulsions; Etoposide; Linear Models; Male; Mice; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2018 |
Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Treatment Outcome | 2017 |
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report.
Topics: Antineoplastic Agents, Phytogenic; Biopsy; Cytotoxins; Etoposide; Female; Fluorodeoxyglucose F18; Hemangioma; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Middle Aged; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Splenectomy; Splenic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2018 |
Autologous stem-cell transplant for metastatic renal medullary carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Sickle Cell Trait; Transplantation, Autologous | 2018 |
Paclitaxel and etoposide-loaded Poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Interactions; Drug Liberation; Etoposide; Humans; Microspheres; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2018 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators | 2020 |
Potentialization of anticancer agents by identification of new chemosensitizers active under hypoxia.
Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; DNA Fingerprinting; Drug Synergism; Etoposide; Hep G2 Cells; Humans; Paclitaxel; Thiosemicarbazones | 2019 |
Outcomes of fertility-sparing surgery in ovarian juvenile granulosa cell tumor.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Child; Cisplatin; Etoposide; Female; Fertility Preservation; Granulosa Cell Tumor; Humans; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan | 2020 |
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neoplasm Staging; NF-E2-Related Factor 2; Paclitaxel; Prognosis; Spheroids, Cellular; Survival Rate | 2020 |
Correction of Damaging Effects of Cisplatin-Containing Polychemotherapy on the Intestinal Epithelium with Tussilago farfara L. Polysaccharides.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cisplatin; Eosine Yellowish-(YS); Etoposide; Female; Hematoxylin; Histocytochemistry; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Paclitaxel; Plant Extracts; Polysaccharides; Tussilago | 2019 |
Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Retrospective Studies; Risk; ROC Curve; Sensitivity and Specificity; Severity of Illness Index | 2020 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Lung Neoplasms; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins | 2020 |
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Treatment Outcome | 2021 |
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Capecitabine; Carboplatin; Dexamethasone; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Oxaliplatin; Paclitaxel; Pre-Exposure Prophylaxis; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2020 |
Placental site trophoblastic tumour: five challenges of patient clinical management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chorionic Gonadotropin; Cisplatin; Consolidation Chemotherapy; Dactinomycin; Etoposide; Female; Humans; Hysterectomy; Lung Neoplasms; Lymph Node Excision; Methotrexate; Paclitaxel; Pregnancy; Puerperal Disorders; Salpingectomy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms | 2021 |
Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Etoposide; Glioblastoma; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats; Survival Rate | 2021 |
Therapeutic strategy analysis of patients with advanced stage high-grade neuroendocrine cervical cancer: A real-world multicenter study.
Topics: Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms | 2022 |
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms | 2022 |
Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Docetaxel; Doxorubicin; Drug Delivery Systems; Emulsions; Etoposide; Fluorouracil; Humans; Paclitaxel; Solubility; Surface-Active Agents | 2022 |
Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.
Topics: Acquired Immunodeficiency Syndrome; Bleomycin; Cost-Benefit Analysis; Etoposide; HIV Infections; Humans; Kenya; Paclitaxel; Sarcoma, Kaposi; Vincristine | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
LC-MS-MS Determination of Cytostatic Drugs on Surfaces and in Urine to Assess Occupational Exposure.
Topics: Chromatography, Liquid; Cyclophosphamide; Cytostatic Agents; Epirubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Occupational Exposure; Paclitaxel; Tandem Mass Spectrometry; Vinorelbine | 2023 |
Metabolomics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Etoposide.
Topics: Brain Neoplasms; Etoposide; Glioblastoma; Humans; Paclitaxel; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2022 |
Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Etoposide; Humans; Mice; Nanoparticles; Paclitaxel; Prodrugs; Serum Albumin, Human | 2023 |
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Conservative Treatment; Etoposide; Female; Humans; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Pregnancy; Prognosis; Retrospective Studies; Young Adult | 2023 |